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ABSTRACT 
Since its discovery as the etiological agent of AIDS in 1983, HIV-1 has been the focus of 
unrelenting research into an effective vaccine to control viral infection. Neutralizing 
antibodies constitute a correlate of immune protection for most available vaccines, but the 
induction of these antibodies against HIV-1 has become a major challenge. The HIV-1 
envelope glycoprotein has evolved to evade neutralizing antibodies in an extraordinary 
way, yet a vaccine that can stimulate such antibodies remains the best hope to provide 
sterilizing immunity. The existence of a group of monoclonal antibodies, such as IgG1b12, 
2G12, 2F5 and 4E10, capable of neutralizing a broad range of primary isolates signals 
vulnerable areas on the envelope glycoprotein. Furthermore, passive transfer of these 
antibodies can completely protect against viral challenge in animal models. The epitopes 
recognized by these antibodies are being intensely pursued as vaccine targets, in the hope 
of inducing such specificities. This thesis encompasses a series of studies on characterizing 
the epitopes recognized by these broadly cross-reactive monoclonal antibodies in the 
context of subtype C viruses. HIV-1 subtype C is responsible for the vast majority of 
infections worldwide, however, until recently, little research has been done on these 
viruses in contrast to the well characterized subtype B strains. Chapter Two describes the 
characterization of paediatric subtype C viruses for their sensitivity to IgG1b12, 2G12, 2F5 
and 4E10. This study was done because of a planned clinical trial of some of these 
antibodies as post-exposure prophylaxis to prevent mother-to-child HIV-1 subtype C 
transmission. Only the MAb 4E10 was able to neutralize all the viruses tested, while 
IgG1b12 was only partially effective. 2F5 and 2G12 did not neutralize any of the viruses. 
The conclusion was that only 4E10 and IgG1b12 would be suitable for use as prophylactic 
agents in a population where HIV-1 subtype C is prevalent. Given that subtype C viruses 
were found to be largely insensitive to 2G12 neutralization, the commonly absent glycan at 
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position 295 was introduced into envelope glycoproteins from this clade. The work 
presented in Chapter Three explores the requirements of the 2G12 epitope on the 
envelopes of subtype C viruses. However, this antibody binding site was not readily 
reconstituted, suggesting structural differences from other HIV-1 subtypes in which the 
2G12 epitope is naturally expressed. Chapter Four describes the study of 4E10 resistant 
virus quasispecies isolated from a seven year old perinatally HIV-1 infected child, in 
whom anti-MPER antibodies were found. Determinants of 4E10 neutralization were 
mapped to the epitope of this antibody in the MPER, as well as to the cytoplasmic tail, in 
particular, to four amino acids in the LLP-2 region. The role of neutralizing antibodies in 
natural HIV-1 subtype C infection was examined in Chapter Five by following the 
development of autologous and heterologous neutralizing antibodies in 14 patients during 
the first year of infection. Potent but relatively strain-specific neutralizing antibody 
responses were detected within 3-12 months of infection. The magnitude of the responses 
was associated with shorter V1-to-V5 envelope length and fewer glycosylation sites, in 
particular in the V1-V2 region. Furthermore, anti-MPER and anti-CD4i neutralizing 
antibodies were detected in some individuals; however, they were not associated with 
neutralization breadth. Finally, in Chapter Six these results are analyzed collectively, in the 
context of the latest findings in the field, and suggestions for further research are discussed. 
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1.1 BACKGROUND 
Human Immunodeficiency Virus type 1 (HIV-1) has infected more than 65 million people 
worldwide since 1983 when it was first described as the cause of the Acquired Immune 
Deficiency Syndrome (AIDS). In 2007, more than 33 million people were estimated to be 
living with HIV-1, 2.5 million became newly infected and around 2.1 million lost their 
lives to AIDS (UNAIDS 2007, www.unaids.org). Although antiretroviral therapies are 
highly effective in treating HIV infections, only a vaccine constitutes a practical and cost-
effective intervention to control the spread of the HIV/AIDS pandemic.  
A major challenge for the development of an HIV vaccine has been to determine which 
immune responses should be elicited for protection. Currently licensed anti-viral vaccines 
are mostly effective against acute viral infections, conferring protection mainly through 
neutralizing antibodies. However, cell mediated immune responses are crucial in the 
control of established chronic virus infections such as cytomegalovirus (CMV), Epstein-
Barr virus (EBV) and Herpes simplex virus (HSV) (Pantaleo and Koup, 2004) for which it 
has been more difficult to develop effective vaccines. In the case of HIV, the correlates of 
immune protection have not been clearly identified. Early studies have showed that 
immunization with the outer envelope protein (gp120) of HIV-1 induced antibodies that 
inhibited viral entry. However, subsequent clinical studies demonstrated that these 
antibodies did not protect against HIV-1 infection (Gilbert et al., 2005). This was later 
explained by their inability to neutralize primary HIV-1 isolates, despite having activity 
against neutralization sensitive T-cell line adapted strains (TCLA) that were used in the 
initial studies (Mascola and McNeil, 1995). These observations led many to question the 
relevance of this vaccine approach (Mammano et al., 1995, Moore et al., 1995, Schonning 
et al., 1998). Soon after, a new generation of vaccine candidates emerged which aimed to 
prime cellular immunity, specifically CD8+ cytotoxic T-lymphocytes (CTLs). Indeed, 
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virus-specific CTLs are thought to be responsible for controlling viral replication in the 
acute phase of HIV infection (Koup et al., 1994). Furthermore, studies on simian 
immunodeficiency virus (SIV)-infected monkeys have shown that immunogens capable of 
inducing CTL responses can reduce viral set point and slow disease progression (Letvin, 
2005). These observations suggested that vaccines capable of eliciting strong T-cell-
mediated immune responses may be beneficial even if they do not induce sterilizing 
immunity. However, this type of response does not clear the virus reservoirs and resistance 
variants can emerge later in infection (Barouch et al., 2003). The failure of a recent “test-
of-concept” clinical trial of Merck’s candidate HIV-vaccine, which aimed to stimulate 
CTL responses, has further questioned this vaccine approach (http://www3. 
niaid.nih.gov/news/newsreleases/2007/step_statement.htm). There is renewed interest in 
neutralizing antibodies, prompted mainly by several observations that passive transfer of 
neutralizing antibodies are able to confer sterilizing immunity in animal studies (Mascola, 
2002). In addition, it has been shown that although effector T cells can limit viral 
replication, they are not able to assist humoral immunity to prevent the establishment of 
initial infection (Mascola et al., 2003). As such, an enormous effort is currently being 
invested in the “intelligent” design of immunogens capable of inducing broadly cross-
reactive neutralizing antibodies against HIV-1 primary isolates. Such an endeavor requires 
not only an in-depth understanding of the viral envelope glycoprotein structure and 
function, but also the role of neutralizing antibodies in natural HIV-1 infection. 
1.2 HIV ENVELOPE GLYCOPROTEIN 
The main targets of the anti-HIV neutralizing antibodies are the glycoprotein spikes on the 
virus envelope membrane. This glycoprotein complex interacts with the CD4 and 
coreceptor molecules present on the surface of target cell initiating the viral entry process. 
The functional envelope spike consists of a trimer of heterodimers formed by two 
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glycoproteins, gp120 (the exterior envelope glycoprotein) and gp41 (the transmembrane 
glycoprotein). Three gp120 molecules interact non-covalently with three gp41 units 
forming an oligomer, where the trimeric structure is maintained by the interactions 
between the gp41 domains.  
In infected cells, the envelope glycoprotein is synthesized as a single polypeptide of 
approximately 845 to 870 amino acids in the rough endoplasmic reticulum (Allan et al., 
1985). The extensive addition of N-linked high-mannose sugar chains forms the gp160 
glycoproteins, which assemble into trimers (Earl et al., 1990). These oligomers are then 
transported to the Golgi apparatus, where accessible glycans are trimmed and modified to 
complex-oligosacharides. In the trans-Golgi, cellular proteases cleave the gp160 molecule 
into gp120 and gp41 (Decroly et al., 1997, Hallenberger et al., 1997). The mature spikes 
are then transported to the cell membrane, in particular to the detergent-insoluble 
membrane domains, known as lipid rafts (Rousso et al., 2000), where the virus assembly 
take place and the envelope spikes are incorporated into the budding virions. 
1.2.1 The gp120 molecule 
The amino acid sequence of gp120 consists of five relatively conserved regions (C1-C5) 
interposed with five variable regions (V1-V5) which, with the exception of V5, are 
bracketed by cysteines forming disulfide bonds (Leonard et al., 1990) (Figure 1.1). Gp120 
is a highly glycosylated protein with half of its mass being N-linked glycans (Lasky et al., 
1986), far more glycosylated than the surface proteins from other retroviruses of similar 
size such as HTLV-1 and MuLV (Polonoff et al., 1982). Two types of N-linked 
glycosylations are found on the surface of gp120, mannose-rich and complex glycans. 
Structural modelling suggests that the high mannose glycans are clustered on one side of 
the surface while the complex glycans are localized within a distinct region of the gp120 
(Zhu et al., 2000). 
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Figure 1.1 Organization of gp120 in linear and two-dimensional diagrams. (a) Schematic representation 
of the envelope glycoprotein precursor. Digestion by cellular proteases, at the indicated cleavage sites 
(vertical arrows), releases the signal peptide, the gp120 and the gp41 molecules. The locations of the variable 
loops (V1-V5) in gp120 are indicated in red. (b) Gp120 two-dimensional diagram adapted from McCaffrey, 
et al., 2004. The small numbers indicate the amino acid positions in the HxB2 sequence. Arrows indicate the 
positions involved in the co-receptor binding site and asterisks indicate the residues involved in CD4 binding. 
In both diagrams the N-linked glycosylation sites are represented by the oligosaccharides structures expected 
in those positions: U-shaped branches for the complex glycans and tri-branched for the mannose rich glycans. 
a) 
b) 
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1.2.1.1 Structural domains of gp120 
Full-length gp120 has eluded structural analysis due to its lack of stability. To obtain 
crystal structures, HIV-1 and SIV gp120s have been deglycosylated and the N- and C-
terminals, V1/V2 and V3 regions truncated, to generate what is commonly referred to as 
the “gp120 core”. The first gp120 structure was obtained using the gp120 core of an HIV-1 
virus stabilized with the D1D2 fragment of CD4 and a CD4 induced epitope-binding 
antibody (17b) (Kwong et al., 1998). Based on this structure, gp120 is organized into three 
regions: the inner domain, the outer domain and the bridging sheet (Figure 1.2b). The inner 
domain is formed mainly by the C1 and C5 regions and is largely devoid of glycans. It has 
long been suggested that this domain constitutes the major contact interface with the gp41 
trans-membrane unit (Helseth et al., 1991, Moore et al., 1994). The outer domain is 
heavily glycosylated and modelling of the envelope oligomer suggests that these glycans 
cover the solvent-exposed part of the spike, protecting it from antibody recognition. In 
between the outer and inner domains is the bridging sheet region, formed by four anti-
parallel β-sheets: β2 and β3, which constitute the stem of the deleted V1/V2 loop; and the 
β20 and β21 of the C4 region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Crystal structures of gp120 core in unliganded and CD4-bound conformations. Ribbon 
diagram of (a) the unliganded SIV gp120 and (b) the HIV-1 liganded gp120 structures are depicted from the 
CD4 perspective. The structural domains are colored; green for the inner domain, blue for the outer domain 
and yellow for the bridging sheet. Variable loops stems and the β-sheets that form the bridging sheet are also 
indicated. Figures were created in PyMol from the PDB data files 2BC4 (Chen et a., 2005) and 1GC1 
(Kwong et al., 1998). 
a) b) 
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More recently the gp120 of an SIV virus was resolved in the absence of CD4. This 
unliganded gp120 structure is presumed to represent the native state conformation (Chen et 
al., 2005). In contrast to the outer domain, which has a similar conformation as the 
liganded form, the inner domain and the bridging sheet revealed a very altered structure, 
suggesting that binding of CD4 induces radical conformational changes in these regions. 
The bridging sheet observed in the CD4 bound conformation appears segregated in the 
native structure (Figure 1.2a), with the β2 and β3 sheets, laying proximal to the inner 
domain, displaced 20-25 Å from the β20 and β21 loop.  
A third gp120 structure was resolved using an HIV-1 gp120 core that included the V3 
loop, complexed to CD4 and the Fab X5 (Huang et al., 2005). In this structure the core 
resembles the liganded conformation. The V3 loop protrudes as an elongated structure 
from two anti-parallel β-sheets in the outer domain. A disulphide bond between β12 and 
β13 stabilizes its base, while a long flexible stem extends away from the core ending in a 
conserved β-turn tip. The trimeric model of this structure predicts the projection of the tip 
30 Å towards the cell membrane, consistent with its positioning towards the coreceptor 
molecule (Huang et al., 2005) (Figure 1.3). However, it is not clear if V3 displays an 
extended structure in the context of the native oligomer. It has been suggested that the V3 
is partially occluded by the V1/V2 loop of the adjacent protomer in the trimeric envelope 
glycoprotein, and it is only extended after CD4 interaction (Wyatt et al., 1998). 
The widely assumed trimeric structure of the envelope complex has recently been 
visualized using cryo-electron tomography microscopy by two separate groups (Zanetti et 
al., 2006, Zhu et al., 2006). Both studies have demonstrated similar dimensions and 
threefold symmetry for the envelope spike, but the actual map images displayed some 
distinct features (Figure 1.4). The Zhu et al. structure presents multiple lobes emanating 
from the core and tripod-like configuration of gp41, while the Zanetti et al. reconstruction 
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 constitutes a smooth structure with only three clear lobes and a single stem linking with 
the membrane (Roux and Taylor, 2007). These differences have been attributed to the 
techniques used for data collection and analysis (Subramaniam, 2006). Despite these 
limitations, this rapid evolving methodology promises to assist in solving the native 
structure of the envelope spike in more physiologically relevant environments, i.e. in the 
context of a viral or cell membrane. 
                              
Figure 1.4: Electron tomography density maps of the SIV envelope spike.  Side (a, c) and top (b, d) 
views of the 3D structure of SIV envelope glycoprotein as reported by Zhu et al., 2006 (a, b) and Zanetti et 
al., 2006 (c, d). Figure adapted from Roux and Taylor, 2007. 
 
1.2.1.2 Functional sites of gp120 
1.2.1.2.1   CD4 binding site (CD4bs) 
The CD4bs of gp120 constitutes a conformational region suggested to be only apparent in 
the context of the liganded structure of gp120. It is characterized by a hydrophobic pocket 
at the interface of the inner domain, the bridging sheet and outer domain, where the side 
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chain of the Phe43 of CD4 is buried, otherwise known as the “Phe43 cavity” (Figure 1.5). 
In the unliganded structure many of the residues involved in the interaction with CD4 are 
distributed around the interface of the inner and outer domain which is lined with 
hydrophobic residues (Chen et al., 2005). It has been proposed that the CD4 molecule first 
interacts with the internal face of the conformationally stable outer domains. However, this 
interaction is not energetically favorable, incurring a substantial drop in entropy (Kwong et 
al., 2002), and is only stable at the cell surface where the presence of multiple CD4 
molecules, binding the trimer simultaneously, increases the avidity of this interaction 
(Zhou et al., 2007). The binding of CD4 induces large conformational changes in the inner 
domain, which leads to the formation of the bridging sheet and coreceptor binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
 
Figure 1.5: CD4 and CCR5 binding surface on unliganded and liganded gp120. Molecular surface 
diagrams of the unliganded SIV and liganded HIV-1 gp120 core structures are shown from similar 
orientations. The residues interacting with the CD4 receptor, as documented by Zhou et al., 2007, are shown 
in red surrounding the Phe43 cavity. The amino acids involved in CCR5 binding, as determined by Rizzuto et 
al., 1998, are depicted in green in the vicinity of the V3 loop stem, shown in yellow. 
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1.2.1.2.2 Coreceptor binding site 
In addition to CD4 receptors, HIV requires the presence of coreceptor molecules on the 
surface of the target cells. Most primary isolates use the β-chemokine receptor CCR5 as an 
entry coreceptor, although some viruses undergo a coreceptor switch mainly to CXCR4 
usage. Other minor coreceptors such as CCR1, CCR2b, CCR3, CCR8, CXCR6 
(Bonzo/STRL33), Bob/GPR15 and GPR1, have also been shown to mediate virus entry in 
vitro, although their use in vivo is less certain (Moore et al., 2004). The V3 loop has been 
mapped as the major determinant of coreceptor switching, which demonstrates its 
involvement in the coreceptor-binding site. Other conserved structures of gp120 also form 
part of this functional region, such as the bridging sheet and the stem of the V3 loop 
(Rizzuto and Sodroski, 2000, Rizzuto et al., 1998). These residues are segregated in the 
unliganded gp120 structure and only converge after CD4 binding, to form a conserved 
pocket that harbors the sulfotyrosines on the N terminus of CCR5 (Figure 1.5). This 
interaction zips the flexible V3 stem into a rigid β-hairpin (Huang et al., 2007). However, 
it is not clear if these changes occur before or after the tip of the V3 interacts with the 
second extracellular loop of CCR5 (Huang et al., 2007). 
1.2.2 The gp41 molecule 
The gp41 molecule is a transmembrane glycoprotein, that is less variable and less 
glycosylated than gp120. It interacts non-covalently with gp120 and is responsible for 
maintaining the trimeric structure of the envelope glycoprotein, although its structure in the 
native conformation is unknown. 
Gp41 constitutes a class I fusion glycoprotein structurally homologous to the fusion 
proteins of other enveloped viruses such as orthomyxo-, paramyxo-, retro-, filo- and 
coronaviruses (Dimitrov, 2004). The linear amino acid sequence of gp41 can be divided 
CHAPTER 1: INTRODUCTION 
 
 12 
into an ectodomain, a very conserved membrane spanning domain and a particularly long 
cytoplasmic tail (Figure 1.6). 
1.2.2.1 gp41 ectodomain and the fusion process 
Several important features are present in the ectodomain of gp41 (Figure 1.6). The N-
terminus hydrophobic glycine-rich peptide is essential for membrane fusion activity. This 
fusion peptide is linked, through a flexible polar segment, to a coiled-coil forming 
amphipathic α-helix (Heptad repeat-1, HR1 or N-helix). A centrally located disulphide-
bonded loop connects the HR1 to a second amphipathic α-helix  (HR2 or C-helix), which 
is followed by the membrane proximal external region (MPER). 
 
  
 
Figure 1.6: Schematic representation of the functional domains of gp41. (a) Functional motifs are 
indicated in a linear diagram of gp41. The membrane-spanning domain separates the ectodomain from the 
cytoplasmic tail. The disulphide loop and the glycans in the ectodomain are represented as S-S and Y, 
respectively. (b) Schematic diagram and (c) side and (d) top view of the atomic model of the six-helix bundle 
formed by the heptad repeats of gp41 shown in red and yellow (PDB code 1QBZ, Yang, et al.,1999). 
 
In free virions most of the gp41 ectodomain is buried by gp120, protecting this conserved 
fusion machinery from recognition by the immune system (Figure 1.7a). Only the MPER is 
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thought to be exposed, as neutralizing antibodies against this region (2F5 and 4E10) are 
able to bind the native structure before receptor engagement (de Rosny et al., 2004, Zwick 
et al., 2001). The interface of gp41 with gp120 is not clearly discerned. However, cysteine 
scanning of the disulphide-bonded region of gp41, and the C1 and C5 regions in the inner 
domain of gp120 has identified residues that are able to covalently link these subunits 
(Binley et al., 2000a). Although the gp41 native structure in the prefusogenic state is 
unknown, experimental evidence suggests that this conformation may be stabilized through 
interactions with the inner domain β-sandwich (Yang et al., 2003), which prevents the 
large interactive surfaces of HR1 and HR2 from collapsing into the highly stable six-helix 
bundle conformation (Weissenhorn et al., 1997). It has been suggested that in this 
prefusogenic state, the fusion peptide is in close proximity to the MPER (Lorizate et al., 
2006) and the HR1 region does not form a coiled-coil structure (Mische et al., 2005).  
     
Figure 1.7: Model of the envelope-mediated fusion process. (a) Cartoon showing the envelope trimer 
before CD4 and co-receptor binding. The gp41 regions are depicted in the same color scheme as in Figure 
1.6. The MPER region (green) may be exposed in the native conformation of the envelope. (b) After CD4 
and coreceptor engagement, gp41 assumes an extended three-helix rod conformation inserting the fusion 
peptide (blue) into the host cell membrane. (c) The formation of the metastable six-helix bundle mediates the 
fusion of the virus membrane into the cell membrane.  
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Upon CD4 and coreceptor binding the inner domain rearranges, destabilizing the structure 
of gp41 and inducing the pre-hairpin intermediate state. In this structure, the three gp41 
molecules are associated in a trimeric coiled-coil in parallel orientation (Furuta et al., 1998, 
Jiang et al., 1993, Munoz-Barroso et al., 1998, Wild et al., 1994). The fusion peptide is 
released and inserted into the target cell membrane (Figure 1.7b). Although the existence 
of this structure is not clear, it has been extrapolated from the mechanism of the influenza 
virus hemagglutinin (HA) (Carr and Kim, 1993) and the ability of HR1 binding peptides, 
such as T-20 (Enfurvitide, DP-178), to trap this conformation and inhibit the fusion 
process (Furuta et al., 1998). 
The fusion-intermediate is brief, with the three HR2 helices rapidly folding into the 
hydrophobic grove on the surface of the HR1 coiled-coil trimer in an anti-parallel manner, 
creating a six-helical bundle structure that facilitates the fusion process by bringing the 
viral and cell membranes together (Figure 1.7c). This conformation is extremely stable, 
and it is believed that the free energy released during this step contributes substantially to 
overcome the energy barrier of the membrane fusion process (Chan and Kim, 1998). This 
post-fusion configuration of the ectodomain of gp41 has been structurally characterized 
(Weissenhorn et al., 1997), however it is not clear how the transition from the three-helix 
rod takes place (Chan et al., 1997). It has been suggested that the formation of the six-
helical bundle is only completed once the fusion pore has formed (Markosyan et al., 2003). 
1.2.2.2 Cytoplasmic tail of gp41 
The membrane spanning domain (MSD) precedes an approximately 150 amino acids long 
segment in the intracellular compartment, known as the cytoplasmic tail (CT). The CT of 
HIV is, as for most lentiviruses, particularly long compared to other members of the 
Retroviridae family (Hunter and Swanstrom, 1990, Kalia et al., 2003). 
Multiple studies have demonstrated the critical role of the CT in virus assembly and 
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envelope incorporation. Mutations or deletions in the matrix protein (p17) affect envelope 
incorporation, which can be reversed by compensatory mutations in the CT of gp41, 
demonstrating the interaction between these two proteins (Freed and Martin, 1996). 
Several lines of evidence suggest that Gag processing and the fusion machinery of the 
envelope glycoprotein are connected via the CT. The p55 precursor in the immature virion 
interacts with the CT of gp41 inhibiting the fusion process, as shown in protease defective 
viruses, while deletion of the CT disassociates these events (Murakami et al., 2004). This 
mechanism may avoid early fusion of immature particles that are not able to establish 
infection.  
The CT of gp41 contains a number of highly conserved functional motifs (Figure 1.6). The 
membrane proximal Tyr-based endocytosis (YxxΦ) motif and the dileucine motif at the C-
terminus mediate clathrin-dependent endocytosis, alter intracellular localization, and 
regulate envelope expression and incorporation in the virion (Byland et al., 2007, Day et 
al., 2004, LaBranche et al., 1995, West et al., 2002, Wyss et al., 2001, Ye et al., 2004). 
One or more palmitoylated cysteines (C764 and C837) are implicated in targeting envelope 
glycoprotein to lipid rafts and mutation of these cysteines to alanine decrease envelope 
incorporation and infectivity (Bhattacharya et al., 2004, Rousso et al., 2000). Three highly 
conserved amphipathic α-helices, known as “lentivirus lytic peptide” domains (LLP-1, 
LLP-2, and LLP-3) are implicated in interacting with the plasma membrane, decreasing 
bilayer stability, affecting envelope cell surface expression and incorporation into virus 
particles (Kalia et al., 2003, Piller et al., 2000, Wyss et al., 2005). They have also been 
described as calmodulin-binding domains that promote Fas-mediated apoptosis of infected 
cells (Micoli et al., 2006, Srinivas et al., 1993). 
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1.3 NEUTRALIZING ANTIBODIES 
1.3.1 Neutralizing antibody responses in HIV-1 infected patients 
In HIV-1 infection, antibodies capable of blocking virus infection in vitro develop in 
almost all individuals, although whether they are able to perform this function in vivo is 
less clear. Their absence during the acute phase of infection, when viral levels are brought 
under control, suggests that cellular immune responses may be more critical during this 
period (Moog et al., 1997, Koup et al., 1994). The earliest neutralizing antibodies can be 
detected after 3-12 months of infection, however, there is considerable variation in the 
kinetic, magnitude and breadth of this response (Kelly et al., 2005, Moog et al., 1997, 
Pellegrin et al., 1996, Richman et al., 2003, Wei et al., 2003). In general, the initial 
neutralization response is narrow, only effective against early autologous viruses (Li et al., 
2006a, Moog et al., 1997, Richman et al., 2003) and some T-cell line adapted strains 
(Pilgrim et al., 1997). Nevertheless, the appearance of neutralization escape variants soon 
after the autologous response has developed, supports the notion that these antibodies exert 
immunological pressure on the virus (Wei et al., 2003, Richman et al., 2003). Antibodies 
capable of neutralizing heterologous viruses develop later in infection, with only a small 
percentage of chronically infected patients having broadly cross-reactive antibodies against 
multiple HIV-1 viruses (Braibant et al., 2006, Donners et al., 2002, Pilgrim et al., 1997). 
The nature of the antibodies in broadly cross-reactive sera, as well as why breadth 
develops so rarely, is not well understood. It is clear, however, that a threshold of viremia 
is necessary to induce neutralizing antibodies, demonstrated by their absence in individuals 
on highly active antiretroviral therapy (HAART) and in “elite controllers” (Bailey et al., 
2006, Binley et al., 2000b, Montefiori et al., 2001). In chronic infection, high viremia has 
been correlated with neutralization breadth (Deeks et al., 2006). On the other hand, rapidly 
progressing individuals, who lack control over viremia, usually display low neutralizing 
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antibody titers, but this may be attributed to a general immune suppression (Cecilia et al., 
1999, Pilgrim et al., 1997). 
A recent study has suggested that neutralizing antibodies might protect from HIV-1 
superinfection, as this is more likely to occur during the early phase of infection when 
these antibodies are absent (Smith et al., 2006). Other studies have shown that maternal 
neutralizing antibodies can exert powerful protective and selective effects during perinatal 
HIV-1 transmission with resistant strains establishing infection in infants (Dickover et al., 
2006, Wu et al., 2006). 
1.3.2 Mechanisms of evasion from neutralizing antibodies 
HIV-1 has developed multiple escape mechanisms to avoid neutralization. The shedding of 
gp120 monomers diverts the immune system towards structures otherwise not found on the 
native trimer (Wyatt and Sodroski, 1998). The envelope spike is heavily glycosylated, with 
the poorly immunogenic glycans shielding antibody access to the peptidic structure 
(Johnson and Desrosiers, 2002). Furthermore, changes in glycan packing yield viruses 
resistant to the autologous neutralizing antibody response. This neutralization escape 
mechanism is referred as an “evolving glycan shield” (Wei et al., 2003). 
The trimeric nature of the envelope glycoprotein shields conserved regions, while exposing 
relative amorphous highly glycosylated loop structures. These regions tolerate high levels 
of variation and therefore can easily escape from neutralizing antibodies (Wyatt et al., 
1998). Multiple studies have suggested that the V1/V2 loops cover conserved epitopes 
involved in the coreceptor binding site of the neighboring protomer (Kwong et al., 2000), 
as deletion of these variable loops confers sensitivity to antibodies targeting this region 
(Sullivan et al., 1998, Wyatt et al., 1995). The coreceptor binding site is only transiently 
exposed after receptor engagement and thus out of antibody reach (Labrijn et al., 2003, Wu 
et al., 1996). The CD4bs on the other hand is exposed for functional reasons, however, a 
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distinct type of camouflage, called “entropic masking”, protects it. Binding to this epitope 
requires the fixation of the otherwise flexible gp120, imposing an entropic barrier for the 
high affinity antibody binding required for neutralization (Kwong et al., 2002). 
1.3.3 Broadly neutralizing antibodies 
Despite all these defense mechanisms, a few rare broadly neutralizing monoclonal 
antibodies (nMAb) have been isolated from HIV-1 subtype B infected individuals. These 
MAb neutralize many primary isolates from different genetic subtypes, indicating some 
conserved structures on the envelope glycoproteins. Their epitopes include regions in gp41 
(2F5 and 4E10), the CD4bs (b12), and part of the carbohydrate-masked “silent face” of 
gp120 (2G12). Crystallographic analysis of these antibodies have revealed that they 
underwent remarkable structural adaptations to attain virus recognition (Burton et al., 
2005).  
Passive immunization of primates challenged with chimeric simian–human 
immunodeficiency virus (SHIV) strains has shown that human nMAbs can protect against 
infection and are effective against intravenous (Baba et al., 2000, Mascola et al., 1999), 
oral (Hofmann-Lehmann et al., 2001) or intravaginal challenges (Mascola et al., 2000, 
Parren et al., 2001, Veazey et al., 2003). In cases where transmission occurs they can 
ameliorate disease by blunting the peak of viremia and lowering the viral set point 
(Ferrantelli et al., 2007). A recent study in humans showed that in some HIV-infected 
individuals these nMAbs can reduce the rate of viral rebound following a structured 
treatment interruption (Trkola et al., 2005). Furthermore, the existence of 2G12 escape 
variants in some of the treated patients demonstrated that this nMAb was indeed functional 
in vivo (Manrique et al., 2007, Nakowitsch et al., 2005).  
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1.3.4 Neutralizing antibody epitopes  
1.3.4.1 CD4bs: b12 epitope 
The neutralizing antibody b12 was obtained as a Fab through a phage display library 
strategy (Burton et al., 1991). The Fab b12 as well as the IgG1 recombinant MAb derived 
from it, IgG1b12, occlude the CD4bs on gp120 and prevents CD4 attachment (Burton et 
al., 1994, Roben et al., 1994). A key element of the CD4bs is a recess that forms a contact 
site for the Phe43 protruding from a loop of CD4 (Wyatt and Sodroski, 1998). The first 
crystal structure of IgG1b12 revealed that the protruding heavy chain complementarity 
determining region 3  (CDRH3) was unusually long, allowing it to access the CD4 binding 
pocket (Saphire et al., 2001). However, it was only the recent crystallized structure of the 
Fab b12 in complex with gp120 that clarified the mechanism behind this antibody 
neutralization. The b12 interactions with gp120 are mainly with residues in the structurally 
invariant outer domain (Figure 1.8). As a result, the b12 binding site, in contrast to the 
CD4bs, does not differ considerably from the pre- to post-attachment forms of gp120 
(Zhou et al., 2007), explaining the previously shown low entropic cost of this interaction 
(Kwong et al., 2002). 
 
 
 
 
 
 
 
 
 
Figure 1.8: CD4 and b12 recognition of gp120. Ribbon diagram of gp120 bound to CD4 (yellow) and b12 
(green-light blue) as obtained by Zhou, et al., 2007. The gp120 outer domain (red), inner domain (grey) and 
bridging sheet (dark blue) are indicated in both structures. 
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1.3.4.2 Silent face: 2G12 epitope 
2G12 recognizes a unique epitope on the surface of gp120 that is not directly associated 
with the receptor binding sites (Sanders et al., 2002a). Antibody mapping studies using 
monomeric gp120 showed that 2G12 forms a unique competition group in that no other 
MAb is able to prevent its binding to gp120 and vice versa (Moore and Sodroski, 1996). 
2G12 binds to high mannose and/or hybrid glycans, with mannose residues as essential 
components. Mutagenesis studies have implicated the glycans at positions 295, 332 and 
392 in gp120 as being the most critical for 2G12 binding (Sanders et al., 2002a, Scanlan et 
al., 2002). The X-ray crystallography of this MAb in complex with mannose 
oligosaccharides, unveiled a unique antibody structure in which the two heavy chain 
variable domains (VH) interlock creating a swapped dimer arrangement (Figure 1.9). This 
creates an extended paratope that allows the recognition of a large oligomannose moiety.  
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Model of the nMAb 2G12 in contact with glycans on gp120. The heavy chains (VH) of 2G12 
(yellow and purple) interlock with the light chains (VL) (cyan), forming a unique domain-swapped antibody 
structure. The extended 2G12 idiotope has been modeled to interact with Man9GlcNAc2 groups (red), 
attached to the N332 and N392 residues of gp120 (grey) with its primary combining site. The glycan at N339 
interacts with a secondary combining site formed by the VH/VH’ interface. Figure was adapted from Calarese, 
et al., 2003. 
 
2G12 MAb
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The authors concluded that 2G12 binds to the N-linked glycans at position 332 and 392 in 
the primary combining sites, with a potential interaction with glycn 339 at the VH/VH’ 
interface of the antibody (Calarese et al., 2003). They also proposed that the glycan at 
position 295 plays an indirect role by preventing further processing of the glycan at 332 
and maintaining its oligomannose structure as the one recognized by 2G12.  
1.3.4.3 MPER: 2F5 and 4E10 epitopes 
2F5 and 4E10 recognize two adjacent highly conserved epitopes in the extreme C-terminal 
of the gp41 ectodomain (Figure 1.10). This region is particularly attractive for vaccine 
design because it mediates the viral entry process and is highly conserved between viral 
strains. 
The 2F5 epitope has been mapped to the motif ELDKWA at the end of the HR2 region of 
gp41 (Muster et al., 1993), where the core residues D664, K665 and W666 are 
indispensable for antibody recognition (Zwick et al., 2005). Structural data of 2F5 MAb-
epitope complexes shows that this region adopts an extended conformation with a type I β-
turn at the core of the epitope. Interestingly, the hydrophobic apex of the CDR H3 loop of 
2F5 does not interact with the epitope directly (Ofek et al., 2004). It has been suggested 
that this region mediates interactions with the epitope-proximal viral membrane, 
explaining early evidence that 2F5 binding was enhanced in the presence of lipids 
(Grundner et al., 2002).  
The nMAb 4E10 recognizes a contiguous epitope at the C-terminus of the 2F5 binding 
region (Stiegler et al., 2001, Zwick et al., 2001). Mutagenesis experiments have 
demonstrated that the residues W672, F673 and W680 of the Trp-rich region of gp41 are 
indispensable for recognition by 4E10 (Zwick et al., 2005). The crystal structure of 4E10 
bound to a 13-residue peptide revealed that this epitope assumes an unusual helical 
conformation. The hydrophobic face of this amphipathic helix is buried in the antibody 
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combining site, where amino acids W672, F673, I675 and T676 are the key residues in this 
interaction (Cardoso et al., 2005). Further structural analysis of this epitope has extended it 
to the motif 672-WFx(I/L)(T/S)xx(L/I)W-680, where x does not play a major role in 4E10 
binding (Cardoso et al., 2007). 
 
   
4E10
2F5
 
 
 
 
Figure 1.10: Models of the nMAbs 4E10 and 2F5 Fabs bound to their epitopes. The structure of the 4E10 
and 2F5 Fabs bound to their peptide epitopes, obtained by Cardoso, et al., 2005 and Ofek, et al., 2004, 
respectively, are shown in the context of the envelope spike (a) obtained by Zhu, et al., 2006, and (b) in the 
vicinity of the viral membrane. Figures were obtained from the IAVI report, 2006 (www.iavireport.org) and 
Burton, et al., 2005 
 
a) 
b) 
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1.3.4.4 V3 loop 
In addition to those described above, there are other epitopes able to induce neutralizing 
antibodies, but in a more limited way. This is the case for the V3 loop of gp120, which was 
previously considered the principal neutralizing determinant (Palker et al., 1988, Rusche et 
al., 1988). Later research demonstrated that this was only applicable to TCLA strains, 
where numerous passages in cell culture rendered these viruses highly sensitive to 
neutralization by anti-gp120 monoclonal antibodies, patients’ sera, and soluble forms of 
CD4 (Wrin et al., 1995, Verrier et al., 2001, Follis et al., 1998). The mechanism by which 
sensitivity to neutralizing ligands is acquired is not clear and is manifested only in the 
context of the functional trimeric envelope spike. Monomeric gp120s derived from either a 
TCLA strain or a primary isolate exhibit similar affinities for sCD4 (Moore et al., 1991). 
By contrast the trimeric envelope glycoprotein of TCLA viruses bind the CD4 molecule 
more efficiently than the primary isolate (Moore et al., 1992, Kabat et al., 1994, Platt et al., 
1997). The exposure of epitopes on TCLA viruses may reflect an optimization of the virus-
cell interactions, particularly the CD4-gp120, in the absence of selective pressure provided 
by serum-neutralizing antibodies (Moore et al., 1995). 
The V3 loop is less important for primary isolate neutralization, presumably because this 
region is occluded in the trimeric structure prior to receptor binding. Furthermore, due to 
the variable nature of this region, most anti-V3 antibodies are isolate-specific. However, a 
group of these antibodies recognizes conformation-sensitive epitopes on V3 and they are 
able to neutralize a range of primary isolates. This is the case for the MAb 447-52D, which 
recognizes the GPGR motif at the tip of the V3 and main-chain atoms along the N-terminal 
side of the loop (Gorny et al., 1992, Huang et al., 2005, Stanfield et al., 2004). 447-52D 
neutralizes laboratory strains (Gorny et al., 1992, Gorny et al., 1993) and clinical isolates 
from various clades (Conley et al., 1994, Nyambi et al., 1998). Although, its activity is 
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limited to viruses containing the GPGR sequence at the apex of V3 loop, the relatively 
broad neutralizing activity of 447-52D highlights the existence of conserved structures in 
the V3 loop and makes this region a potential vaccine target. 
1.3.4.5 Coreceptor binding site and/or CD4 induced epitope (CD4i) 
The binding of CD4 to gp120 induces conformational changes that lead to the formation of 
the coreceptor binding site and enhanced binding of a group of antibodies, referred to as 
CD4i antibodies, such as: 17b, 21c, 23e, 48d, 49e (Xiang et al., 2002), X5 (Moulard et al., 
2002), E51 (Xiang et al., 2003) and 412d (Xiang et al., 2005). Crystal structure and 
mutagenesis data have shown that the epitope recognized by these antibodies overlaps 
significantly with the highly conserved coreceptor binding site (Huang et al., 2005, Kwong 
et al., 1998, Xiang et al., 2002, Xiang et al., 2003). In many cases these antibodies mimic 
the coreceptor molecule by presenting sulfated tyrosine in their CDRH3 (Huang et al., 
2007, Huang et al., 2004). CD4i antibodies are commonly found in HIV-infected 
individuals (Decker et al., 2005) suggesting that this epitope is highly immunogenic. 
Despite the extremely broad recognition of CD4i antibodies, neutralization is usually 
impaired. Several studies have shown that virus strains that do not require CD4 for entry 
are highly sensitive to neutralization by CD4i antibodies (Kolchinsky et al., 2001, Edwards 
et al., 2001). Moreover, CD4 dependence assures that this immunogenic and conserved 
region is only exposed after receptor engagement, where the close proximity of the viral 
and host membranes somewhat restricts the access to this region. This is supported by the 
fact that small forms of these antibodies, such as Fabs or single chains, display better 
neutralizing activity (Labrijn et al., 2003). Taken together, these observations preclude this 
epitope as a good target for vaccine design.  
CHAPTER 1: INTRODUCTION 
 
 25 
1.4 IMMUNOGEN DESIGN FOR INDUCING NEUTRALIZING ANTIBODIES 
The lack of success of monomeric gp120 to induce neutralizing antibodies against primary 
isolates called for novel vaccine design strategies. Multiple approaches have been tested in 
the pursuit of an immunogen capable of inducing a broadly cross-reactive neutralization 
response some of which are described below. While the majority of these candidates have 
been able to induce neutralizing antibodies, they are usually only successful against viruses 
that are generally neutralization sensitive or closely related to the antigenic strain. 
1.4.1 Native trimeric envelope glycoproteins as immunogens 
The observation that neutralization correlates with antibody-binding to the native trimeric 
envelope glycoprotein (Fouts et al., 1997, Sattentau and Moore, 1995) suggested the use of 
immunogens that resemble the oligomeric protein on the surface of the virus. 
Immunization with virus like particles (VLPs), pseudovirions and chemically inactivated 
viruses, constitute the most direct approaches to present the native trimer to the immune 
system (Buonaguro et al., 2005, Crooks et al., 2007, Grovit-Ferbas et al., 2000, McBurney 
et al., 2007, Quan et al., 2007, Race et al., 1995, Wagner et al., 1996). A key issue in these 
methodologies is the elicitation of antibodies to other cell membrane proteins incorporated 
in the VLPs, which could confound the interpretation of these results by showing 
neutralizing activity. Furthermore, the presence of gp120-gp41 monomers and gp41 
stumps on these particles could induce non-neutralizing antibodies (Moore et al., 2006). To 
circumvent these issues it has been suggested that recombinant envelope trimers in 
proteoliposomes (EnvPL) be used as immunogens (Grundner et al., 2002). This approach 
was shown to be superior to monomeric gp120 in rabbit immunization experiments 
(Grundner et al., 2005).  
Another strategy to mimic the native envelope structure has been the use of soluble 
recombinant trimers as immunogens. This approach entails the production and purification 
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of stable trimeric proteins. A widely followed method has been the use of soluble gp140 
with a deleted cleavage site to avoid gp120 shedding (Barnett et al., 2001, Bower et al., 
2004b, Srivastava et al., 2002, Yang et al., 2002, Yang et al., 2001, Zhang et al., 2001, 
Zhang et al., 2007). Further stabilization has been achieved by introducing heterologous 
trimerization domains such as the yeast transcription factor GCN4 (Yang et al., 2000). The 
cleavage defective soluble ectodomain construct YU2 gp140 (-/GCN4) has been shown to 
elicit neutralizing antibodies with some breadth compared to monomeric gp120 in mice, 
rabbits and guinea pigs (Grundner et al., 2005, Li et al., 2006c, Yang et al., 2001). 
However, observations that uncleaved forms of the envelope preferentially bind non-
neutralizing antibodies suggest that they do not optimally resemble the native glycoprotein 
(Herrera et al., 2005, Pancera and Wyatt, 2005). As an alternative to preserving the 
cleavage site, other groups have stabilized the gp120-gp41 interaction by introducing inter-
subunit disulphide bonds (SOS) (Binley et al., 2000a, Binley et al., 2002) with further 
trimerization improvement by introducing a helix-disturbing mutation in the HR1 of gp41 
(SOSIP) (Beddows et al., 2007, Beddows et al., 2005, Sanders et al., 2002b). This 
approach once again rendered antigens superior to monomeric gp120, but they still failed 
to elicit broadly neutralizing antibodies (Beddows et al., 2007). It is possible that these 
manipulations do not achieve presentation of the native structure of the envelope 
glycoprotein. However, immunization experiments with non-stabilized gp140 oligomers 
were also limited in their ability to induce neutralizing antibodies (Kim et al., 2005).  
Strain-specific features may determine the stability of the trimeric structure as well as its 
capacity to induce broadly cross-reactive neutralizing antibodies (Rademeyer et al., 2007). 
A recent study showed that the R2 isolate-based uncleaved gp140 oligomer, derived from a 
patient with broadly cross-reactive neutralizing antibodies, elicited antibodies capable of 
neutralizing several heterologous viruses from multiple clades and constitutes the most 
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successful immunogen reported to date (Zhang et al., 2007). 
1.4.2 Exposure of cryptic epitopes (CD4i epitope) 
Other strategies have involved the exposure of cryptic epitopes, such as the conserved 
CD4i epitope, by deleting variable loops (Barnett et al., 2001, Gzyl et al., 2004, Kim et al., 
2003, Lian et al., 2005, Srivastava et al., 2003) or glycosylation sites (Bolmstedt et al., 
2001, Quinones-Kochs et al., 2002) (Nkosi et al. unpublished). Most of these 
modifications have been done in the context of soluble forms of the stabilized envelope 
trimer. An alternative to exposing the CD4i epitope has been to co-express gp120 with the 
CD4 subunit D1D2 (Fouts et al., 2002). This immunogen generated antibodies capable of 
inhibiting entry of several HIV-1 isolates, but concerns about the induction of anti-CD4 
antibodies have been raised. To bypass this difficulty, mimetic forms of CD4 have been 
used, such as the gp120-M9 construct (Varadarajan et al., 2005); or gp120 liganded to the 
A32  antibody, which induces CD4i epitope exposure (Liao et al., 2004), but both these 
methods failed to elicit broadly neutralizing antibodies. 
1.4.3 Epitopes of nMAbs as immunogens 
Another group of immunogens are based on the conserved epitopes recognized by the 
broadly nMAbs b12, 2G12, 2F5 and 4E10, aiming to recapitulate their antigenic site 
(Burton et al., 2004).  
The CD4bs is of particular interest as it is exposed on the surface of the virus for functional 
reasons. However, with the exception of IgG1b12, neutralizing antibodies to this region are 
not readily induced due to thermodynamic constraints (Kwong et al., 2002, Zhou et al., 
2007). The stabilization of the gp120 monomer in a CD4-bound conformation has been 
proposed as a method to overcome this barrier. Rationalized structure manipulations, such 
as the introduction of cavity filling mutations and inter-domain disulfide bonds, have 
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stabilized gp120 conformations that bind CD4 with minimal entropy (Dey et al., 2007, 
Zhou et al., 2007). Immunization with trimeric gp120-GCN4 with cavity filling mutations 
induced CD4i antibodies, but showed little improvement in eliciting neutralizing 
antibodies (Dey et al., 2007). Induction of anti-CD4bs antibodies, such as IgG1b12, has 
also been pursued through other strategies, such as glycan masking of non-neutralizing 
epitopes in the gp120 molecule, to focus the antibody response on the b12 epitope 
(Pantophlet et al., 2003, Pantophlet et al., 2004). While this approach succeeded in 
masking dominant non-neutralizing epitopes, it did not improve the neutralization response 
in immunized rabbits (Selvarajah et al., 2005). Assisted by new structural data on the b12 
binding site and the biochemical properties of this interaction (Zhou et al., 2007), new 
strategies to induce b12-like antibodies are under development (Liu et al., 2007, Phogat et 
al., 2007). 
Attempts to reproduce the high mannose clustering recognized by 2G12 using synthetic 
glycosides and Man9 sugars conjugated to carrier molecules or synthetic scaffolds have 
been pursued (Dudkin et al., 2004, Geng et al., 2004, Lee et al., 2004, Li and Wang, 2004, 
Wang et al., 2004). While some of these synthetic oligosacarides inhibit the binding of 
2G12 to gp120, their ability to induce neutralizing antibodies has not yet been reported. 
Another problem with these immunogens is their internal flexibility. Further strategies to 
enhance the immunogenicity to this epitope were discussed in a recent review by Scanlan 
et al. (Scanlan et al., 2007). They comprise the use of antigenic carriers and adjuvants that 
can break immunotolerance and the inclusion of antigenic carbohydrates such as rhamnose 
in these synthetic constructs. 
Structural data has shown that the nMAb 4E10 binds to a helical conformation of its 
epitope. On this basis, stabilization of a peptide containing the 4E10 epitope in a helical 
conformation has been pursued in the design of a better immunogen (Cardoso et al., 2007). 
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Further manipulations to hide the non-binding site of this helix, taking membrane 
interactions into consideration, have also been proposed (Cardoso et al., 2007, Zwick, 
2005). Other researchers have designed miniproteins containing the MPER in the context 
of a proteoliposome or the Hepatitis B surface antigen S1 protein (Ofek et al., 2004). 
Immunogenicity trials of these variants in a prime-boost regimen with native gp160 trimer 
have been suggested (Ofek et al., 2004). In a recent study, the MPER was engrafted into 
the V1/V2 region of gp120, but anti-MPER antibodies were not induced (Law et al., 2007). 
The knowledge obtained from the 2F5 and 4E10 antibody structures bound to their 
corresponding epitopes, is currently being exploited in the design of epitope-scaffold 
immunogens by in silico screening of potential carrier proteins (Ofek et al., 2007, Phogat 
et al., 2007). This inventive methodology promises to produce new candidates soon to be 
tested in pre-clinical studies. 
1.4.4 Multivalent and centralized immunogens 
To overcome the genetic diversity of HIV, multivalent or centralized envelope 
immunogens have been used in preclinical and clinical trials. The first strategy combined 
the envelopes of multiple HIV-1 clades in one immunization protocol to increase the 
breadth of the immune responses (Cho et al., 2001, Pal et al., 2005, Rollman et al., 2004, 
Seaman et al., 2005, Wang et al., 2006). The second approach minimizes epitope diversity 
by artificially designing envelope genes representing consensus or ancestral sequences of 
those available in at the Los Alamos HIV Database. This strategy is based on the 
assumption that these sequences will be more closely related to circulating variants than 
the circulating variants will be to one another (Nickle et al., 2003). Six centralized 
immunogens have been generated to date; two consensus M, CON6 (Gao et al., 1996) and 
CON-S (Liao et al., 2006); subtype-specific consensus ConC (Kothe et al., 2006) and 
ConB (Kothe et al., 2007), and ancestral Anc1-EnvB (Doria-Rose et al., 2005) and AncC 
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(Kothe et al., 2006). Of them, the newer consensus, CON-S, was shown to elicit greater 
neutralization breadth. This suggests that as more sequences are entered into the database, 
better coverage of envelope variability will be attained. 
1.4.5 Other factors that contribute to vaccine design 
In addition to antigen design, progress has been made in other areas that contribute to the 
envelope glycoprotein immunogenicity. DNA prime and recombinant protein boost 
immunization regimens have been shown to improve the neutralizing antibody responses 
(Beddows et al., 2005, Law et al., 2007, Lian et al., 2005, Shu et al., 2007, Wang et al., 
2005). Other combinations such as DNA prime-VLP boost (Buonaguro et al., 2007a) and  
DNA prime-viral vector boost (Gomez et al., 2007, Seaman et al., 2007, Shinoda et al., 
2006) have also been promising.  
Novel adjuvant formulations have been tried in conjunction with newly designed 
immunogens. The GlaxoSmithKline adjuvants, AS01B, AS02A and AS03 have been 
shown to enhance the neutralizing titers induced by a soluble trimeric envelope in 
comparison to the more commonly used Ribi adjuvant (Li et al., 2006c, Zhang et al., 
2007). The fusion of the innate activator C3d to an envelope construct proved to enhance 
immunogenicity (Bower et al., 2004a, Bower et al., 2006). Another formulation involving 
the co-delivery of GM-CSF DNA was shown to increase avidity of the antibody response 
(Robinson et al., 2006) and IL-21 and IL-15 gene delivery can increase the level of anti-
HIV IgG and the longevity of immune responses (Bolesta et al., 2006). The use of CpG as 
a mucosal adjuvant was shown to enhance humoral and cellular immune responses in these 
compartments (Kang and Compans, 2003). 
Comparison between the numerous vaccine candidates and immunization strategies has 
been difficult as various neutralization assays and viral strains have been used in these 
different studies. This constitutes a major complication in the decision about which 
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immunogens to advance into clinical trials. Mascola et al, suggested the use of cloned 
envelopes in a pseudovirion neutralization assay in combination with standardized viral 
panels to evaluate the neutralization responses elicited by candidate vaccines (Mascola et 
al., 2005). To date, two panels have been assembled, which include viruses from early 
subtype B and C infections (Li et al., 2005, Li et al., 2006b). Furthermore, a multitier 
system groups these viruses according to neutralization sensitivity, allowing comparisons 
of the potencies and breadths of the elicited antibodies (Mascola et al., 2005). 
1.5 GENETIC SUBTYPES OF HIV-1 AND NEUTRALIZATION IMMUNOTYPES 
An important goal in the development of an effective HIV-1 vaccine is to overcome the 
extensive genetic heterogeneity of the virus. HIV-1 viruses have been divided in three 
groups based on their nucleotide sequences: group M (main), group O (outlier), and group 
N (non-M non-O) (McCutchan et al., 1996). Group M, the largest one, is further divided 
into genetic subtypes or clades: A, B, C, D, F1, F2, G, H, J and K, plus at least 20 
circulating recombinant forms (Buonaguro et al., 2007b). Subtype C is the most prevalent 
in the world, being common in India and the southern African countries of Botswana, 
Zimbabwe, Malawi, Mozambique, and South Africa. Subtype B is dominant in North 
America and Western Europe and has been, until recently, the major focus for vaccine 
development. Although subtypes are a useful means to categorize HIV-1, the relevance of 
genetic subtype for vaccine design is uncertain. Genetic subtypes do not readily 
corresponds to neutralization serotypes and there is no compelling evidence to suggest that 
HIV-1 positive sera better neutralize viruses from the same clade than viruses from another 
clade (Kostrikis et al., 1996, Moore et al., 1996, Moore et al., 2001, Nyambi et al., 2000, 
Weber et al., 1996). However, some have reported stronger intraclade neutralization for 
subtype A/E (Mascola et al., 1996) or a regional clustering amongst subtype C viruses 
(Bures et al., 2002). The difficulties associated with finding neutralization immunotypes 
CHAPTER 1: INTRODUCTION 
 
 32 
have been attributed to the variability of the neutralization titers and specificities in HIV-1 
positive sera, as well as the variability of the neutralization sensitivity of the viruses and 
the high background-to-noise ratio of the methodologies used in these studies. A recent 
study, which used monoclonal antibodies in a highly reproducible single round 
neutralization assay, defined five neutralization immunotypes of HIV-1 somewhat 
associated with genetic clades (Binley et al., 2004). In this case, the absence or presence of 
some antibody epitopes could be defined in the envelope sequence and correlated with the 
observed phenotype. The fact that many of the epitopes recognized by these broadly cross-
reactive nMAbs have been pursued as targets for vaccine design, underscores the 
importance of their study in the context of other HIV-1 subtypes. 
1.6 OBJECTIVES OF THIS STUDY 
The aim of this work was to characterize the neutralizing antibodies epitopes on the HIV-1 
subtype C envelope glycoprotein as well as the neutralization response that develops in 
HIV-1 subtype C infection, in particular the antibody specificities associated with this 
response.  
• Firstly, the sensitivity of HIV-1 subtype C envelope glycoproteins to the broadly 
neutralizing monoclonal antibodies 2G12, IgG1b12, 4E10 and 2F5 were 
determined. The presence of the epitope recognized by these antibodies was 
assessed and compared to the neutralization phenotype.  
• Given that subtype C viruses were found to be insensitive to 2G12 neutralization, 
envelope clones generated in the above study were used in an attempt to 
reconstitute the 2G12 epitope in subtype C envelopes. This information was further 
used to assess the antigenic conservation of subtype C envelopes in comparison 
with their subtype B counterparts. 
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• The 4E10 epitope is very conserved amongst HIV-1 viruses and an important target 
for vaccine design. The identification of an HIV-1 subtype C infected individual 
carrying 4E10 resistant variants allowed the study of the determinants of 4E10 
sensitivity in the envelope gene of these viral quasispecies. 
• Finally, the kinetics of the neutralization response during natural HIV-1 subtype C 
infection was analyzed by examining the development of autologous and 
heterologous neutralizing antibodies in 14 individuals during the first year of 
infection. In addition, the presence of antibody specificities, such anti-MPER and 
anti-CD4i neutralizing antibodies, was also assessed. 
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Abstract: 
The broadly neutralizing monoclonal antibody (MAb) 4E10 recognizes a linear epitope in 
the C-terminus of the membrane proximal external region (MPER) of gp41. This epitope is 
particularly attractive for vaccine design because it is highly conserved amongst HIV-1 
strains and neutralization escape in vivo has not been observed.  Multiple env genes were 
cloned from an HIV-1 subtype C virus isolated from a 7 year old perinatally infected child 
who had anti-MPER neutralizing antibodies. One clone (TM20.13) was resistant to 4E10 
neutralization as a result of an F673L substitution in the MPER. Frequency analysis 
showed that F673L was present in 33% of the viral variants and in all cases was linked to 
the presence of an intact 2F5 epitope. Two other envelope clones were sensitive to 4E10 
neutralization, but TM20.5 was 10-fold less sensitive than TM20.6. Substitutions at 674 
and 677 within the MPER rendered TM20.5 more sensitive to 4E10, but had no effect on 
TM20.6. Using chimeric and mutant constructs of these two variants, we further 
demonstrated that the LLP-2 domain in the cytoplasmic tail affected the accessibility of the 
4E10 epitope, as well as virus infectivity. Collectively, these genetic changes in the face of 
a neutralizing antibody response to the MPER, strongly suggested immune escape from 
antibody responses targeting this region. 
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Introduction: 
The membrane proximal external region (MPER) of the HIV-1 envelope glycoprotein 
comprises the last 23 amino acids, from residues 660 to 683, of the extracellular domain of 
gp41 just before the transmembrane domain. This region has attracted a lot of attention in 
the field of HIV vaccinology due to some particular features: i) it is the target of two of the 
few broadly neutralizing monoclonal antibodies against HIV-1, namely 4E10 and 2F5, ii) it 
has been shown to be important in the fusion process and therefore in viral entry (11, 28), 
and iii) it is a highly conserved linear region among all HIV-1 subtypes. 
 
The MAb 4E10 recognizes an epitope containing the sequence NWF(D/N)IT (30, 38) in 
the tryptophan-rich region of gp41. Mutagenesis experiments have shown that residues 
W672, F673 and W680 are indispensable for 4E10 recognition (37). Crystal structures of 
the Fab 4E10 in complex with a peptide containing the epitope, illustrate that residues 
W672, F673, I675 and T676 are the key residues in this interaction (7). A more recent 
study extended the 4E10 epitope to the motif WFx(I/L)(T/S)xx(L/I)W (residues 672-680), 
where the amino acids marked with an x do not play a major role in 4E10 binding (6). The 
sequence ELDKWA (residues 663-667) immediately N-terminal to the 4E10 epitope, is the 
target of the 2F5 MAb (21). Mutagenesis studies had revealed that the amino acid motif 
DKW is required for recognition by this MAb (37), and structural studies have 
demonstrated that these three residues are deeply buried in the interface with 2F5 (25). 
While 4E10 neutralizes viruses from all HIV-1 subtypes, 2F5 fails to neutralize subtype C 
and some subtype D viruses and this can be directly correlated to changes in the antibody 
epitope (3, 14). 
 
Despite the high level of conservation of the MPER and its importance in the fusion 
process, multiple studies have demonstrated that mutations in this region do not necessarily 
impair viral infectivity (5, 37). It has been proposed that this region is not targeted by the 
host immune response and therefore is not under diversifying selection pressure (36). 
Recent studies have addressed the question of whether HIV-1 infection induces the 
production of neutralizing antibodies that target the MPER. The presence of such 
antibodies was assessed using a novel strategy where the HIV-1 MPER was engrafted onto 
an SIV (35) or HIV-2 envelope (F. Bibollet-Ruche et al., presented at the Keystone 
Symposium on HIV Vaccines, Keystone Resort, Keystone, CO, 2006). These studies 
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indicated that antibodies with specificities such as 4E10 and 2F5 are rarely produced (J. M. 
Decker et al., presented at the Keystone Symposium on HIV Vaccines, Keystone Resort, 
Keystone, CO, 2006) (35), however, other anti-MPER antibodies were detected in around a 
third of HIV-1 infected patients (F. Bibollet-Ruche et al., presented at the Keystone 
Symposium on HIV Vaccines, Keystone Resort, Keystone, CO, 2006).  It remains unclear 
what the effect of such antibodies is on the viral population, as escape variants have not 
been described.  
 
In this study we characterized HIV-1 subtype C viral quasispecies with different 
sensitivities to the MAb 4E10. We explored the genetic determinants of these phenotypes 
as well as the anti-MPER antibody response that developed in the individual from whom 
this virus was isolated. 
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Methods: 
Cloning of envelope genes and production of pseudovirions:  Proviral DNA extracted from 
in vitro infected PBMCs was used to amplify full-length envelope genes using the primers 
envA and envM (13). The 3Kb PCR fragments were cloned into an expression vector and 
used to generate Env-pseudotyped viruses as previously described (14). 
Envelope sequencing: gp41 was amplified from viral RNA from culture supernatant by 
nested RT-PCR using published primers (9, 13)  and cloned using the TOPO TA Cloning® 
Kit (Invitrogen Corporation, Carlsbad, CA). The gp41 and gp160 clones were sequenced 
using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied 
Biosystems, Foster City, CA) and resolved on an ABI 3100 automated genetic analyzer. 
The sequences were assembled and edited using Sequencher v.4.0 software (Genecodes, 
Ann Arbor, MI).  
Single cycle neutralization assay: Neutralization was measured as a reduction in luciferase 
gene expression after a single round infection of JC53bl-13 cells with Env-pseudotyped 
viruses (20). Briefly, 200 TCID50 of pseudoviruses in 50 µl were incubated with 100 µl of 
serially diluted MAbs, CD4-IgG2, plasma or T-20 (Enfurvirtide) in DMEM with 10% FBS 
in a 96-well plate, in triplicate for 1 h at 37°C. A 100 µl of JC53bl-13 cells (1x104 
cells/well) containing 75 µg/ml DEAE dextran (Sigma-Aldrich, St. Louis, MO) was added 
and the cultures were incubated at 37°C in 5% CO2. Infection was determined 48 hours 
later using the Bright GloTM Reagent (Promega, Madison, WI). Luminescence was 
measured in a Wallac 1420 Victor Multilabel Counter (Perkin Elmer, Norwalk, CT). Titers 
were calculated as the inhibitory concentration (IC50) or reciprocal plasma dilution (ID50) 
causing 50% reduction of relative light unit (RLU) compared to the virus control (wells 
with no inhibitor) after subtracting the background (wells without virus infection). 
Virus infectivity and envelope incorporation: The amount of virus was normalized by the 
quantity of p24 pelleted through a 20% sucrose cushion for 2 hours at 20,000g. JC53bl-13 
cells were infected with 10 ng of p24 in the presence of 30 µg/ml DEAE dextran, and 
cultures were incubated at 37°C in 5% CO2 for 48 h. Infection was monitored by 
evaluating the luciferase activity. Envelope incorporation was estimated by Western blot. 
Viral proteins were resolved in a Criterion 4-15% Tris-HCl Gradient Gel (Bio-Rad 
Laboratories, Hercules, CA) and blotted onto a PVDF nitrocellulose membrane (GE 
Healthcare Life Science, Piscataway, NJ). The membranes were blocked overnight with 
5% milk in TBS/0.05% Tween 20 and probed with the anti-gp120 (D7324), anti-gp41 
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(7B2) or the anti-p24 (D7312) antibodies, and developed with an HRP-labeled secondary 
antibody (Sigma) using the enhanced chemiluminescence (ECL) detection system (GE 
Healthcare Life Science, Piscataway, NJ). To determine envelope expression levels, 293T 
cells were transfected with envelope constructs using the Fugene transfection reagent 
(Roche, Applied Science, Indianapolis, IN). The cells were harvested after 48 hours and 
lysated with the non-denaturing lysis buffer, 1%  Triton X-100, 300 mM NaCl, 5 mM 
EDTA, 50 mM Tris-Cl, pH 7.4 with Complete protease inhibitor cocktail (Roche). The 
Western Blot was carried out as described above.  
Site directed mutagenesis: Specific amino acid changes in the HIV-1 and HIV-2 envelope 
glycoproteins were introduced using the QuikChange Site Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). The presence of mutations was confirmed by sequence analysis. 
Construction of chimeric envelope glycoproteins: To construct the gp120-gp41 chimeras, 
the TM20.5 and TM20.6 env plasmids were digested with NdeI and the interchanged 
fragments ligated with T4 DNA Ligase (Invitrogen Corporation). The correct orientation of 
the cloned fragments was determined by a colony PCR with primers T7 and EnvM. The 
ectodomain/cytoplasmic tail chimeras were constructing by overlapping PCR spanning the 
transmembrane domain using the primers: TM20CTfo: 
CAGATCCGTGAGATTAGTGAGCGGATTCTTAG and EnvM, TM20CTre: 
CTAAGAATCCGCTCACTAATCTCACGGATCTG and EnvA. The resultant amplicons 
was cloned into pcDNA3.1D (Invitrogen Corporation, Carlsbad, CA). Chimerism was 
confirmed by sequencing. 
Anti-MPER neutralization assay: This assay was adapted from that previously described 
by Decker et al. (J. M. Decker et al., presented at the Keystone Symposium on HIV 
Vaccines, Keystone Resort, Keystone, CO, 2006) using chimeric HIV-2/HIV-1 MPER 
constructs (F. Bibollet-Ruche et al., presented at the Keystone Symposium on HIV 
Vaccines, Keystone Resort, Keystone, CO, 2006) (15). Briefly, 2000 infectious units of 
virus pre-incubated with plasma/serum at a starting dilution of 1:20 and serially diluted 1:5 
in the presence of normal human plasma/serum, was added to 40% confluent JC53bl-13 
cells, seeded the day before. Infection was measured 48 hours later by evaluating the 
luciferase activity as described above. 
Nucleotide sequence accession numbers: The GeneBank database accession numbers for 
the three env clones described in this study are EU161643-EU161645. 
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Results: 
Discovery of a naturally-occurring 4E10 resistant virus: While characterizing functional 
envelope genes from HIV-1 subtype C viruses isolated from children (14) we identified an 
envelope clone, TM20.13 that was resistant to the MAb 4E10. This was the result of an F 
to L mutation at position 673, which is known from mutagenesis studies to confer 
resistance to 4E10 (37). However, this phenotype has not been previously described in 
patient samples and analysis of sequences in the Los Alamos HIV database suggested that 
this mutation is very rare in group M of HIV-1. This clone was derived from a virus 
isolated from a 7 year old female who was infected perinatally and at the time of blood 
collection had a CD4 count of 334 cells/µl and a viral load of 34,310 copies/ml. Although 
this patient had lymphocytic interstitial pneumonitis she was considered to be a slow 
progressor (8). The virus TM20 was isolated on donor PBMC and used the CCR5 
coreceptor with a V3 sequence typical of subtype C viruses (8). Only a single sample from 
this patient was available. Attempts to obtain additional samples either from this individual 
or from her mother were unsuccessful.    
 
Frequency of the F673L mutation in the TM20 virus isolate: To determine the frequency of 
the F673L mutation in this cultured virus isolate, we analyzed the gp41 sequences of 43 
molecular clones. The molecular clones were generated from 3 independent RT-PCR 
reactions from the viral RNA to ensure that the mutation was not introduced by PCR error. 
The mutation F673L was observed in 14 of the 43 (33%) molecular clones sequenced 
(Figure 1). In total 6 different quasispecies were identified. Interestingly the F673L 
mutation was always present in conjunction with the mutation S665K in the 2F5 epitope, 
as well as a group of associated mutations within the HR2 domain and the cytoplasmic tail 
of gp41 (Figure 1 and data not shown). 
 
Generation and characterization of functional TM20 envelope clones: Full-length 
envelope genes were amplified from the TM20 isolate and cloned into an expression vector 
to generate functional clones. Three envelope clones were pseudotyped and characterized 
for their sensitivity to the broadly neutralizing MAbs 4E10 and 2F5, and the entry inhibitor 
T-20 (Enfuvirtide, Fuzeon, DP178) (Figure 2A). As predicted from the sequence analysis, 
the clone TM20.13 was not neutralized by 4E10, but it was sensitive to 2F5. The other two 
clones were sensitive to 4E10 and resistant to 2F5, but TM20.6 (IC50=1.5 µg/ml) showed at 
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least 10-fold higher sensitivity to 4E10 than the clone TM20.5 (IC50=17.5 µg/ml). There 
were no differences in the neutralization sensitivity of the three clones to T-20, which 
binds to the HR1 region of gp41. In addition, all clones showed similar sensitivity to the 
HIV-1 positive plasma samples BB12 and BB107 (Figure 2B), suggesting that the 
increased sensitivity of the clone TM20.6 to 4E10 was not due to a generally neutralization 
sensitive phenotype. All three clones were resistant to the contemporaneous autologous 
serum (below 50% neutralization), which is typical in HIV-1 infection.  
 
Sequence analysis of functional clones from TM20: The full-length envelope genes of the 
three functional clones were sequenced (Figure 3). The genetic variation observed between 
the clones was consistent with the 7 year duration of infection; however the extent of 
variability from the C1 to C3 region of the gp120 was surprisingly low. Since these clones 
were amplified from in vitro grown virus, we cannot exclude the possibility that 
quasispecies bearing different sequences in this region of the envelope existed in vivo. The 
clone TM20.13 had a F673L mutation in the 4E10 epitope as well as the DKW motif 
intrinsic to the 2F5 epitope, which correlated with the observed phenotypes. TM20.5 and 
TM20.6 were identical in the gp41 ectodomain, except for two amino acids in the MPER at 
positions 674 and 677. Multiple other differences between the clones TM20.5 and TM20.6 
were observed along the gp120 and the cytoplasmic tail of gp41. All three clones had 
conserved HR1 and V3 regions which are involved in T-20 sensitivity (10, 27), consistent 
with the observed equivalent sensitivity to this compound. 
 
Changes in the MPER are partially responsible for the differential sensitivity of TM20.5 
and TM20.6 to 4E10: As noted above, TM20.5 was 10-fold less sensitive to 4E10 than 
TM20.6. These two clones differed in two amino acids in the 4E10 epitope (Figure 3). In 
order to determine if these residues were associated with 4E10 sensitivity we introduced 
the mutations D674N and K677N into TM20.6 by site-directed mutagenesis. These 
changes did not render the TM20.6 mutant more resistant to 4E10 neutralization (Figure 
4). Conversely, when the mutations N674D and N677K were introduced in TM20.5 the 
4E10 IC50 dropped 3-fold suggesting that in some contexts these positions may have an 
effect on antibody binding affinity. 
 
4E10 neutralization of envelope chimeras: These apparently discordant results suggested 
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that regions outside the MPER might influence the sensitivity to 4E10. We therefore 
constructed chimeras in which large regions of the envelope gene were interchanged 
between the TM20.5 and TM20.6 clones (Figure 5). For both clones, the gp120 subunit 
had very little to no effect on the neutralization sensitivity indicating that the major 
determinants of 4E10 sensitivity were in the gp41 region. When the cytoplasmic tail from 
TM20.6 was combined with the ectodomain of TM20.5, which included gp120 and the 
external region of gp41, the resulting chimera Ecto5-CT6 was around 4-fold more sensitive 
than TM20.5. Conversely, Ecto6-CT5 was 3-fold less sensitive than TM20.6. Altogether 
these results suggest that while the major determinants of 4E10 sensitivity are in the 
MPER, the cytoplasmic tail can have a tangible impact on the exposure of this epitope. 
 
Mutations in the LLP-2 domain affect sensitivity to neutralization: The cytoplasmic tail 
sequence of clones TM20.5 and TM20.6 differed by ten amino acid residues (Figure 3), 
four in the lentivirus lytic peptide-2 domain (LLP-2). Frequency analysis showed that the 
LLP-2 sequence of TM20.6 was present in 17% of the quasispecies while 36% had the 
TM20.5 LLP-2 sequence. To determine if variations in LLP-2 were responsible for the 
changes in 4E10 sensitivity in the cytoplasmic tail chimeras, we exchanged the LLP-2 
regions of TM20.5 and TM20.6 by introducing the mutations E783A, T784I, G789V and 
T792L in TM20.5 (TM20.5 LLP2-6) and the converse changes in TM20.6 (TM20.6 LLP2-
5). We tested all constructs for their sensitivity to neutralization by 4E10 and T-20 as well 
as IgG1b12 and CD4-IgG2 which bind to gp120 and block interactions with CD4.   
 
As observed for the chimera Ecto5-CT6, the mutant TM20.5 LLP2-6 became more 
sensitive to neutralization by 4E10 when compared to the parental TM20.5 virus (Figure 
5). Similarly, these changes in the LLP-2 explained the decrease in sensitivity to 4E10 in 
the chimera Ecto6-CT5 when compared to the parental TM20.6. Thus, in both cases, the 
four amino acids in the LLP-2 domain accounted for the altered changes in sensitivity to 
4E10 neutralization. These changes also had a minor effect on the neutralization sensitivity 
for IgG1b12 (Figure 5) and CD4-IgG2 (data not shown) but had no effect on T-20 
neutralization.  
 
In order to look at the combined effects of changes in the MPER and LLP-2 we introduced 
these four mutations into the two MPER mutants to form TM20.5 MPER-6 LLP2-6 and 
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TM20.6 MPER-5 LLP2-5. For TM20.5 the resultant clone showed a 9-fold increase in 
neutralization sensitivity to 4E10 and the IC50 titer decreased to a similar level to that 
obtained for the TM20.6 clone (Figure 5). The opposite mutant, TM20.6 containing the 
MPER and LLP-2 of TM20.5, became 7-fold more resistant to neutralization, but the IC50 
titer remained slightly lower than for TM20.5 (11.3 versus 17.5 µg/ml), suggesting that 
perhaps other areas of the envelope may influence this phenotype. These double mutants 
showed similar sensitivities to IgG1b12 and CD4-IgG2 as the corresponding LLP-2 only 
mutants corroborating that the MPER plays no role in determining sensitivity to these 
reagents.  
 
Effect of the gp120 and cytoplasmic tail switching on envelope incorporation and viral 
infectivity: The LLP-2 domain is a highly conserved cationic amphipathic α-helix with 
calmodulin-binding properties (29), that is involved in cell-to-cell fusion (17, 33), 
neutralization sensitivity (16), envelope cell surface expression (4), envelope incorporation 
into virions and virus infectivity (24). To explore the mechanism behind the effect of the 
cytoplasmic tail on 4E10 neutralization sensitivity, we compared the viral infectivity and 
envelope incorporation of the two TM20 clones and their chimeras.  
 
Chimeras bearing the cytoplasmic tail from TM20.6 (ie gp120(5)-gp41(6) and Ecto5-CT6) 
displayed low infectivity similar to the parental virus (Figure 6A). The TM20.5 
cytoplasmic tail conferred an infectivity advantage to the variants carrying it (ie gp120(6)-
gp41(5) and Ecto6-CT5). Furthermore, the LLP-2 mutants of TM20.5 displayed the same 
reduced infectivity as the Ecto5-CT6, while TM20.6 LLP-2 mutants, like Ecto6-CT5, were 
more infectious (data not shown). This suggested that the increased infectivity conferred 
by the TM20.5 cytoplasmic tail was largely determined by four amino acids in LLP-2.    
 
The levels of envelope incorporation into virus particles and envelope expression were 
determined by Western Blot. The virus input was standardized by using equal quantities of 
p24 antigen, which was confirmed by p24 detection on the blots. The amount of envelope 
incorporated into virions was assessed by staining with the anti-gp120 antibody D7324 and 
the anti-gp41 MAb 7B2 to detect gp160 (Figure 6B). In addition, envelope transfected 
cells were lysed and the levels of envelope expression were determined. Surprisingly, the 
less infectious TM20.6 clone showed greater envelope expression and incorporation into 
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virions than the clone TM20.5. This appeared to be determined by the gp120 as all 
chimeras containing TM20.6 gp120 showed higher levels of envelope irrespective of the 
gp41 sequence. Thus, the differential neutralization sensitivity between the clones could 
not be explained by the levels of envelope on virus particles. These results agree with other 
studies showing that the LLP-2 region can affect viral infectivity without changes in 
envelope incorporation (17, 24). 
 
Evaluation of anti-MPER neutralizing antibodies in the sera from TM20: The variability 
within the MPER among the quasispecies and the concomitant variations in 4E10 
sensitivity, suggested the presence of immunological pressure targeting this region. To 
determine if this was the case, we tested the sera of this patient for antibodies to the 
MPER. We measured the neutralization activity of this serum against chimeric HIV-2 
viruses engrafted with complete or partial HIV-1 MPER sequences (F. Bibollet-Ruche et 
al., presented at the Keystone Symposium on HIV Vaccines, Keystone Resort, Keystone, 
CO, 2006). Using this method we were able to detect anti-MPER antibodies in serum from 
patient TM20 (Figure 7). This serum was able to neutralize viruses that carried the full 
MPER sequence of either subtype B (7312A-C1), C (7312A-C1C) or a more similar match 
to the autologous MPER sequence where positions 671 and 676 were mutated to serine 
(7312A-C1Cm). This neutralization response was mapped to the second half of the MPER 
as evidenced by the neutralization of C4, C4GW and C8, but not C3 or C7. It has 
previously been shown that the 4E10 MAb neutralizes the chimeras, C1, C4 and C6 at 
similar antibody concentrations (J. M. Decker et al., presented at the Keystone Symposium 
on HIV Vaccines, Keystone Resort, Keystone, CO, 2006). Since TM20 sera failed to 
neutralize C6, this suggested the absence of 4E10–like antibodies. However, it partially 
neutralized the C4 chimera that in contrast to C6 includes the W680 residue which has 
been described to be important for 4E10 recognition (37). Taken together, our results 
suggest that the serum from this individual contained anti-MPER antibodies that recognize 
an epitope closely related, but not identical to the 4E10 epitope. 
 
Neutralization of C1C F673L by serum from patient TM20: The mutation F673L observed 
in the clone TM20.13 was introduced in the HIV-2/HIV-1 chimeric virus C1C by site-
directed mutagenesis (C1C F/L). This single mutation conferred resistance to the 4E10 
MAb relative to the sensitive C1C parental virus (data not shown). The TM20 serum was 
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unable to neutralize the C1C F/L mutant virus (Figure 7), suggesting that the F673L 
mutation observed in the clone TM20.13 could indeed be an escape mutation from the anti-
MPER response developed by this patient.  
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Discussion 
In the present study we describe three viral quasispecies from an HIV-1 subtype C infected 
child with different sensitivities to neutralization by the broadly cross-reactive MAb 4E10. 
Neutralization resistance was conferred by a rare mutation F673L in the 4E10 epitope. In 
addition, moderate changes in sensitivity between clones were modulated by secondary 
positions in this epitope and motifs in the cytoplasmic tail. The presence of anti-MPER 
neutralizing antibodies in this individual supports the hypothesis that escape from 
antibody-mediated immune pressure was driving these changes. 
 
The MAb 4E10 has been shown to be the most broadly cross-reactive antibody against 
HIV-1 (3), however it is not a particularly potent antibody, with >1 µg/ml needed to 
neutralize most viruses at 50%. In this study, the clone TM20.13 was resistant to 
neutralization at up to 100 µg/ml of 4E10 due to a mutation at F673L in the MPER. This is 
consistent with a report by Zwick and co-workers who showed that the introduction of the 
F673A mutation conferred resistance to 4E10 neutralization (37). The mutation F673L was 
present in a third of the quasispecies in this virus isolate. However, given that they were 
derived from an in vitro cultured virus, it is not clear if this mutation was present at higher 
or lower frequency in vivo, where neutralizing antibodies were present. While L673 is 
common amongst HIV-1 group O envelope sequences, this substitution is very rare among 
HIV-1 group M viruses in the Los Alamos HIV Sequence Database. The highly conserved 
nature of F673 suggests that this site either performs an important function or is not 
accessible to immune attack, as has been proposed (36). However, we found that virus 
infectivity was not obviously compromised by F673L (data not shown), similar to what 
was observed for the F673A mutant (37). This raises the question as to why this position is 
so highly conserved and under such strong negative selection pressure. Interestingly, in our 
study the F673L mutation was linked with the mutation S665K, which confers 2F5 
sensitivity. All other clones were resistant to 2F5, due to the absence of a K at position 
665, which is typical of subtype C viruses (3, 14). Furthermore, these mutations were 
accompanied in all cases by other mutations in gp41. HIV-1 is known to undergo 
considerable recombination during in vivo and in vitro proliferation (18), so the link 
between these changes may simply be the result of a recombination event between two 
divergent viral quasispecies. However, they could also represent compensatory changes 
associated with the mutation F673L that are required by the virus for survival in vivo. A 
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recent study on in vitro escape from 4E10 neutralization showed the appearance of 
F673L/V mutations in the resistant virus, but these viruses had impaired infectivity (19) 
which may explain why 4E10 escape variants were not observed in passive immunization 
studies with this antibody (22, 31). However, these viruses had no other genetic changes in 
this region, such as those shown here, that might have compensated for this loss of 
function (19). 
 
TM20.5 and TM20.6 showed a 10-fold difference in sensitivity to 4E10. These clones were 
identical in the ectodomain of gp41 except for two positions (674 and 677) within the 4E10 
binding domain. Previous studies have shown that these two residues are dispensable for 
4E10 recognition (7, 37). However, we observed that the introduction of mutations 
N674D/N677K into TM20.5 increased 4E10 sensitivity by 3-fold, suggesting that these 
positions can influence the presentation of the 4E10 epitope. On the other hand, the 
TM20.6 clone did not become more resistant to 4E10 when these two positions were 
changed. Therefore, TM20.6 D674N/K677N which had an identical MPER to TM20.5 
showed a 5-fold difference in neutralization sensitivity to 4E10. This was also noted in 
another study where viruses with identical 4E10 epitopes had different IC50 values (3) 
suggesting that factors outside the MPER affect accessibility of this epitope. Indeed, 
substitutions in the HR1 region of gp41 as well as other factors that affect fusion kinetics 
have been shown to influence sensitivity to this MAb (26, 37). Thus, the observation that 
TM20.5 showed enhanced infectivity compared to TM20.6 may explain why only TM20.5 
was sensitive to changes at positions 674 and 677 in the MPER possibly as a result of a 
limited window of opportunity for neutralization. 
 
We demonstrated that the cytoplasmic tail can modulate sensitivity to neutralization, in 
agreement with other studies (12, 16, 32, 34). Furthermore, we were able to identify four 
amino acids in the LLP-2 domain that affect both neutralization and infectivity. Such 
changes could impact on the amphipathicity of the LLP-2 α-helix and therefore its 
membrane association, resulting in phenotypic differences, as observed here and by others 
(16, 24). It has been shown that deletion of the cytoplasmic tail or changes in this region, in 
particular the LLP-2, determines the fusogenicity of the envelope glycoprotein (1, 17, 24, 
33) which could result in changes in sensitivity to some entry inhibitors (1) and MAbs 
(16). Abrahamyan and co-workers suggested that the cytoplasmic tail hinders the folding 
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of the trimeric coiled-coil into the six-helical bundle resulting in greater inhibition by 
peptides that target the fusion intermediates (1). The fact that we did not observe changes 
in sensitivity to T-20, which also targets this conformation, suggests that the mutations in 
the LLP-2 did not influence this stage of the fusion process. On the other hand, early 
events may have been affected, such as the differential exposure of neutralizing epitopes in 
the native structure or, more likely, a faster kinetic rate from the CD4 bound conformation 
to the trimeric coiled-coil. This may preferentially impact 4E10 neutralization as this 
antibody is capable of binding in the post-attachment stage (2). In agreement with this, we 
found that 4E10 neutralization was more affected by changes in the LLP-2 than 
neutralization by IgG1b12 and CD4-IgG2. 
 
Sensitivity to 4E10 neutralization was due to the combined effects of motifs in the MPER 
and the LLP-2. The two amino acid changes in the MPER and the four amino acid changes 
in the LLP-2 were sufficient to confer the 4E10 sensitive phenotype to TM20.5. However, 
engineering the more resistant phenotype appeared to require other sites in addition to 
these 6 amino acids. The fact that the TM20.6 MPER-5 LLP2-5 mutant showed the same 
sensitivity to 4E10 as the gp120(6)-gp41(5) construct, neither of which reached IC50 levels 
shown by TM20.5, suggested that perhaps sites in gp120 were also involved (Figure 5). 
Interestingly, the two mutations in the TM20.6 MPER, which failed to show any effect on 
their own, appeared to contribute to 4E10 resistance when co-expressed with the four LLP-
2 mutations that increased infectivity; again highlighting the role that infectivity plays in 
determining overall neutralization sensitivity. 
 
The presence of an anti-MPER neutralization response in this patient’s serum supports the 
hypothesis that the observed 4E10 resistant envelope quasispecies constituted escape 
variants. Though the antibodies elicited against the MPER in this patient were not clearly 
4E10-like as evidenced by the inability to neutralize C6, their epitopes overlapped, and as 
for 4E10, the residues F673 and W680 were important for recognition. A recent study with 
the antibody Z13e1 showed that the mutation D674N, as observed in TM20.5, eliminates 
antibody binding (23). Therefore, it is also possible that antibodies similar to Z13, where 
the amino acid at position 674 constitutes a critical residue, might be involved in this anti-
MPER neutralization response.  
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This study strongly suggests that the MPER is indeed immunogenic and accessible to 
antibodies that can drive the evolution of the virus toward escape variants. However, such 
an argument is only demonstrable in the context of a longitudinal study where the 
evolution of changes in the envelope glycoprotein can be tracked over time and in parallel 
to the development of the neutralization response. Considering the interest in the MPER as 
a vaccine target, it is important that the potential of in vivo escape from anti-MPER 
antibodies be clarified in such longitudinal studies. 
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Figure legends: 
FIG 1: Frequency analysis of substitutions in the MPER region of 43 gp41 molecular 
clones obtained from the TM20 isolate. The substitutions K665S and F673L, associated 
with 2F5 and 4E10 resistance, respectively, are underlined and bolded. The functional 
envelope clones corresponding with some of these genotypes are indicated to the left of the 
sequences. 
 
FIG 2: Neutralization of TM20 envelope clones. The three functional clones were tested 
for neutralization by (A) the MAb 4E10, 2F5 and the entry inhibitor T-20 (Enfuvirtide), 
and (B) polyclonal antibodies from two broadly cross-reactive HIV-1 positive plasma and 
autologous contemporaneous sera. The dotted lines indicate 50% neutralization with only 
those values above the line considered positive 
 
FIG 3: Full length amino acid sequences of the functional envelope clones TM20.5, 
TM20.6 and TM20.13. Variable regions, heptad-repeat domains (HR-1 and HR-2), MPER, 
membrane spanning domain (MSD) and lentivirus lytic peptides (LLP-1 and LLP-2) are 
indicated. The mutation F673L in the MPER is underlined. The sensitivity of each of the 
clones to 2F5 and 4E10 neutralization is indicated with R denoting resistance and S 
denoting sensitivity. TM20.6 was extremely sensitive to 4E10 neutralization and is 
indicated with S++. 
 
FIG 4: Changes in positions 674 and 677 in the MPER affect 4E10 neutralization. TM20.6, 
TM20.5 and mutants TM20.6 D674N/K677N and TM20.5 N674D/N677K were tested for 
their sensitivity to neutralization by 4E10. Neutralization was scored as the antibody 
concentration required to reduce infectivity by 50% (IC50). The graph represents the mean 
of three independent experiments. P values are indicated when statistically significant 
differences between the means were observed in a Mann-Whitney nonparametric t-test 
analysis. 
 
FIG 5: Changes in the cytoplasmic tail affect neutralization sensitivity. Schematic 
representation of the chimeras, constructed by exchanging gp120 or cytoplasmic tail 
segments of TM20.5 and TM20.6, and LLP-2 and MPER mutants. All the constructs were 
tested for 4E10, IgG1b12 and T-20 neutralization. The mean IC50 of three independent 
experiments are indicated on the right. The IC50 values of the chimeras and mutants were 
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compared to the parental clones TM20.5 or TM20.6 and the IC50 ratio shown in each case. 
Statistically significant differences between means of the parental and chimeric/mutant 
IC50 values with P values <0.05 and <0.01 in a Mann-Whitney t-test are highlighted in 
light and dark gray respectively. 
 
FIG. 6: Role of gp120 and the cytoplasmic tail on infectivity and envelope incorporation. 
A) JC53bl-13 cells were infected with equal amounts of p24 (10 ng) of each parental and 
chimeric Env pseudotyped virus. Infectivity was determined by luciferase expression 
measured as Relative Light Units (RLU). The bars are colour coded according to the 
cytoplasmic tail carried by the construct, black for TM20.5 and white for TM20.6. B) 
Pelleted virions and C) env transfected cells, were lysed and subjected to SDS-PAGE, and 
visualized by Western blotting with anti-gp120 (D7312), anti-gp41 (7B2) or anti-p24 
(D7312) antibodies. D) Schematic representation of the gp120, gp41 ectodomain and 
cytoplasmic tail encoded by the chimeric constructs. Regions derived from the clone 
TM20.5 are shaded grey and regions derived from TM20.6 are in white. 
 
FIG 7: Anti-MPER neutralization activity present in TM20 serum. The HIV-1 MPER 
sequences introduced into the 7321A HIV-2 chimeric or mutant viruses used in the 
neutralization assay are highlighted in grey. The bolded letters represent the sequence of 
the intact 2F5 and 4E10 epitope. The mutations N671S and T676S in C1Cm and F673L in 
C1CF/L are underlined. The IC50 titers are indicated on the right with those showing 
activity highlighted in grey. 
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Figure 3 
TM20-5     MKVMGIQRNCPQWWIWGILGFWMLCNVVGNKDLWVTVYYGVPVWKEAKTTLFCASDAKGYEREVHNVWATHACVPTDPSP 
TM20-6     -------------------------S----------------------------------------------------N- 
TM20-13    ------------------------------GN----------------------------------------------N- 
  
                                                     ________V1__________ _________V2___ 
TM20-5     QEMVLENVTENFNMWNNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLKCSNITKINDTGEMKNCSFNTTTEVRDRKHNQ 
TM20-6     ---------------D----------V-----------------------R----V------------------------ 
TM20-13    --------------------------------------------------R----V------------------------ 
  
    ______________________________ 
TM20-5     YALFYKLDIVPLSEKSNSSSSSESYRLINCNTSTITQACPKVSFDPIPIHYCTPAGYAILKCNNKTFNGTGPCNNVSTVQ 
TM20-6     ----------------------------------------------------A--------------------------- 
TM20-13    -------------------------------------------------------------------------------- 
  
                                                        _______________V3______________ 
TM20-5     CTHGIKPVVSTQLLLNGSLAEGEIIIRSKNLSDNAKTIIVHLNKSVPIVCTRPNNNTRTSTRIGPGQAFYATGDIIGDIR 
TM20-6     ---------------------E--V------------------------------------------------------- 
TM20-13    ---------------------E--V------------------------------------------------------- 
     
           ____                                                ________________V4_______ 
TM20-5     QAHCNISREDWNKTLDMVERKLKEHFNKTIQFAPSSGGDLEITTHSFNCRGEFFYCNTSGLFNSISNETTTNGTTNGTIT 
TM20-6     --------------------------------------------------------S--R----T-----P-....---- 
TM20-13    -------------------------------------------------------------------------------- 
       
           ___                                        ____V5___ 
TM20-5     IPCRIKQIINLWQEVGRAMYAPPIAGKITCNSSITGLLLVRDGGNEEN...DTEIFRPGGGDMRDNWRSELYKYKVVEIK 
TM20-6     --------------------------N------------S----HT--..KTE--------------------------- 
TM20-13    ----------M---------------N---K-N------SS---TDNSTKPE--T------------------------- 
 
                      gp120 <--> gp41 Ectodomain                ___________________HR1_____  
TM20-5     PLGIAPTEARRRVVEREKRAVGIGAVLLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLKAIEAQQHMLQLTVWG 
TM20-6     ---------K---------------------------------------------------------------------- 
TM20-13    ---------K---------------------------------------------------------------------- 
                       
           _________                                            __________________HR2____ 
TM20-5     IKQLRARVLAIERYLKDQQLLGIWGCSGKLICTTNVRWNTTWSNRTRDDIWNNLTWMQWDKEIDNYTDTIYRLLEESQNQ 
TM20-6     -------------------------------------------------------------------------------- 
TM20-13    ------------------------------------P--D----K---E--------------N--------------I- 
    
           ___   ___________MPER_________ ___        MSD       ->gp41 Cytoplasmic tai l  
TM20-5     QEINEQELLALDSWKNLWSWFNISNWLWYIRIFIMIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLTPNPRGPDRPGG 
TM20-6     ---------------------D--K-------------------------------------------N--------L-E 
TM20-13    --R---------K-N-----LS--------K------------------------------------------------R 
                                                             
                                             __________LLP-2_________           
TM20-5     IEEEGGEQDRDRSVRLVSGFLALFWDDLRSLCLFSYHRLRDFILVTARVVETLGQRGWETLKYLGSLGQYWGLELKKSAI 
TM20-6     ----------------------------------C---------------AI----V--L-----------V-------- 
TM20-13    -----------------------V-----N-------------------------------------------------- 
   
                          __________ LLP-1________ _     2F5   4E10 
TM20-5     SLLDTIAIVVAGGTDRVIEFIQRICRAIRNIPRRIRQGFETALL   R      S 
TM20-6     ----------------I---------------------------   R      S++ 
TM20-13    --------------------------------------------   S      R 
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The induction of neutralizing antibodies constitutes a major focus for the development of 
an HIV-1 vaccine, as it remains the only immune response that has been proven capable of 
completely blocking virus entry in animal models. Despite the fact that HIV-1 has evolved 
many strategies to avoid antibody recognition of the conserved regions in the envelope 
glycoprotein, the existence of a few broadly neutralizing MAbs, such as IgG1b12, 2G12, 
2F5 and 4E10, highlights the presence of “weak spots” that can be targeted for vaccine 
design. These nMAbs were isolated from subtype B infected patients and their epitopes 
have mainly been characterized in viruses from this subtype. Given that subtype C viruses 
are responsible for the majority of the HIV-1 infections worldwide, a growing number of 
researchers have expanded their interest to include these viruses. In this context, this work 
focuses on the study of the neutralizing antibody epitopes in the subtype C envelope 
glycoprotein. 
During the course of this study several subtype C viruses were characterized for their 
sensitivity to neutralization by the above mentioned broadly nMAbs. An overview of the 
neutralization efficacy of these antibodies for viruses from our laboratory is shown in 
Figure 6.1. It encompasses 26 subtype C envelope clones, including the paediatric viruses 
described in Chapter Two, the 14 acute infection viruses studied in Chapter Five and five 
other viruses isolated from chronically infected individuals. In summary, 4E10 constituted 
the most broadly reactive neutralizing antibody, followed by IgG1b12 that was able to 
neutralize around fifty percent of the tested viruses. 2G12 and 2F5 neutralized subtype C 
viruses poorly, in agreement with similar studies by other groups (Binley et al., 2004, Li et 
al., 2006b). The paucity of broadly nMAbs against some HIV-1 clades calls for further 
efforts in search of new antibodies. Furthermore, these reagents might point to new 
potential targets for immunogen design. Given that the existing nMAbs revealed 
vulnerable structures on the envelope glycoprotein, it is appropriate to speculate that other 
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neutralizing antibodies that recognize similar epitopes, on non-subtype B envelopes, might 
also have broad activity, i.e antibodies that recognize a glycan arrangement or antibodies 
against the MPER. On the other hand, such antibodies may not be commonly found in 
HIV-1 infected individuals, as they have all shown extremely unusual features. These 
extraordinary structural adaptations (Burton et al., 2005) may depend on host genetic 
elements, such as the germline antibody repertoire or the case of the flexible hinge region 
of 2G12. Others have suggested that the capacity of the nMAbs 2F5 and 4E10 to recognize 
the lipid bilayer, as a mechanism to access the MPER, is associated with the polyreactivity 
of these antibodies (Haynes et al., 2005a). This suggests that B-cells carrying such 
autoreactive specificities normally would suffer clonal deletion, anergy or receptor editing 
(Haynes et al., 2005b). If this is indeed the case, it constitutes a major challenge to the field 
and a call for a better understanding of the B-cell populations where such unusual 
antibodies originate, as it may inform us how to manipulate the immune system to induce 
such specificities. However, a recent study showed that anti-HIV nMAbs are not 
exceptionally polyreactive, challenging the notion that autoantigen mimicry constitutes a 
mechanism of immunoevasion by HIV-1 (Scherer et al., 2007).  
In our study, resistance to the 2F5 MAb was explained, in most cases, by substitutions in 
the K665 residue to serine (S). Interestingly, the motif DKW of the intact 2F5 epitope was 
present in four viruses that were not sensitive to neutralization by this nMAb (Appendix 
A). However, all three viruses had a glutamine (Q) residue at position 667, which may 
explain their resistance to 2F5. Data from previous studies concur with this reasoning, as 
viruses where position 667 was substituted to Gln or Asp were found to be resistant despite 
the presence of an intact DKW motif (Binley et al., 2004, Li et al., 2005, Li et al., 2006b). 
These substitutions may affect the β-turn conformation recognized by 2F5, as this residue 
is involved in the formation of one of the three intra-molecular hydrogen bonds formed in 
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this epitope (Ofek et al., 2007). While the alanine residue at position 667 is relatively 
conserved in subtype B strains, this position is more polymorphic amongst subtype C 
viruses with common substitutions to K, Q, or D. 
 
Figure 6.1: Percentage of viruses sensitive to neutralization by the broadly nMAbs IgG1b12, 
2G12, 2F5 and 4E10. A total of 26 subtype C viruses from our laboratory were tested against the 
nMAbs. Neutralization titers and specific antibody epitope sequences for each of the viruses are 
detailed in Appendix A. 
 
The common lack of reactivity of the nMAb 2G12 against subtype C viruses has been 
attributed to the absence of a glycosylation site at position 295, as reinforced in Figure 6.1 
and Appendix A. The results presented in Chapter Three showed that the addition of a 
glycan at this position did not effectively reconstitute the 2G12 epitope in two subtype C 
viruses, even when other ancillary glycans were present, suggesting that this epitope may 
be displayed in a distinct conformation in the context of a subtype C core. Given that a 
subtype C gp120 structure has not been resolved, we speculate that it may differ from the 
well-characterized subtype B gp120 core. The following evidence supports this hypothesis; 
some positively selected sites found in subtype C envelopes are under negative selection in 
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subtype B viruses (Travers et al., 2005), some of which map to the C3 region of gp120 
(Choisy et al., 2004, Gaschen et al., 2002). This region includes the α2-helix, which has 
been reported to have a very conserved amphipathic nature in subtype C viruses in 
comparison to its more hydrophobic subtype B counterpart (Gnanakaran et al., 2007). This 
suggests that this helix is more exposed in subtype C envelope glycoproteins. In contrast, 
the V3 loop of subtype C viruses is very conserved. A different pattern of glycosylation 
also distinguishes these subtypes (Zhang et al., 2004), such as the differential occurrence 
of glycosylation sites at positions 295 and 442. Taken together, these observations argue 
that the envelope glycoproteins of these subtypes may have distinct antigenic properties. 
This could have resulted from different selection pressures throughout their epidemic 
history, such as the mode of transmission, host genetics and presence of concomitant 
communicable diseases in these populations. Accordingly, differential glycan 
arrangements might affect viral tropism or affinity for molecules involved in virus binding 
and transport, such as DC-SIGN, mannose binding protein or syndecans (Gallay, 2004, 
Nguyen and Hildreth, 2003, Sanders et al., 2002a). In our study, the glycosylation mutants 
did not show apparent changes in viral entry; however, the effect on viral tropism or 
coreceptor affinity was not assessed. Furthermore, a recent study reported that deletion of a 
glycan increased macrophage tropism (Dunfee et al., 2007), while another study showed 
that in vitro generated 2G12 resistant viruses, became more sensitive to neutralization by 
several mannose-specific lectins (Huskens et al., 2007). Collectively, these observations 
support the necessity to explore whether the distinct glycosylation patterns and, in general, 
the differences between envelope glycoproteins of various subtypes could be the result of 
adaptations to different environmental conditions. 
All but one of the viruses tested here were sensitive to 4E10, supporting the cumulative 
evidence that this is the broadest neutralizing antibody available. The one exception was 
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clone TM20.13, which was further characterized in the work described in Chapter Four. 
This study reinforced the importance of the MPER as a vaccine target, as it suggests that 
neutralizing antibodies to this region can indeed exert pressure on the virus, as evidenced 
by the appearance of escape variants. Due to the small scope of this study, with only one 
blood sample from this interesting case, it is not clear how escape from such antibodies 
occurred and how it affected disease progression. We explored the incidence of anti-MPER 
antibodies in an HIV-1 subtype C acute infection cohort. As presented in Chapter Five, 
four of the 14 studied individuals developed anti-MPER antibodies, however, their sera 
were not able to neutralize multiple heterologous viruses, suggesting that these antibodies 
were not conferring neutralization breadth. On the other hand, the role of these anti-MPER 
antibodies in autologous neutralization is unknown, and it will require further study. 
However, given the conservation of the MPER region, it is unlikely that these antibodies 
mediate type-specific recognition. 
The CAPRISA acute HIV-1 infection cohort gave us the opportunity to scrutinize the role 
of the neutralizing antibody response in natural infection. The work presented in Chapter 
Five is the beginning of a profound study of the evolution of neutralizing antibody 
responses in subtype C infection. In here, neutralization of the early autologous virus was 
detected only after 19 weeks post-infection, despite anti-HIV antibodies being detected as 
early as two weeks, anti-gp41 antibodies at 5-10 weeks and anti-V3 antibodies at 3-10 
weeks post-infection (Alam et al., 2007, Moore et al., 2007). Furthermore, these 
autologous neutralization responses were highly type-specific with limited cross-reactivity 
even at two years post-infection (unpublished observations). The study of the specificities 
associated with this narrow neutralization response has been the subject of a recent study, 
which suggests that the C3-V4 region is a major target of type-specific autologous 
neutralizing antibodies (Moore et al., 2007). It is not clear if this finding can be extended 
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to other HIV-1 subtypes, therefore, it is important to perform a similar study at least in 
subtype B infected individuals. 
Interestingly, in three patients, CD4i antibodies were detected very early in infection. 
Although the role of these antibodies is not clear, it has been proposed that CD4i 
antibodies may influence viral pathogenesis by constraining the virus to CD4 dependence. 
A comprehensive analysis of envelope sequences amplified from single genomes suggests 
that during acute infection there is no immune pressure on the virus as env diversity 
follows a Poisson distribution (Keele et al., 2007). Given that the inferred transmitted 
viruses showed CD4 dependence, no evidence is available to suggest that transmission of 
early virus replication favours CD4 independent variants.  
It is a conundrum for the field as to why there is a delay in the production of neutralizing 
antibodies to HIV-1 and particularly broadly cross-reactive antibodies. While in general 
the induction of neutralizing antibodies requires time to achieve affinity maturation, in 
early HIV-1 infection this period is prolonged because of the absence of an efficient T-
helper response and a general non-specific immunoactivation (Brenchley et al., 2006). 
Furthermore, B-cells producing broadly cross-reactive neutralizing antibodies may have to 
compete with non-neutralizing antibodies to immunodominant epitopes and perhaps with 
non-neutralizing antibodies to the same epitope (Alam et al., 2007) or even type-specific 
neutralizing antibodies. While the initial vaccine response has to deal only with the latter, 
the rapid activation of memory B-cells upon infection is another stumbling block in HIV-
vaccine development. Therefore, extensive research is needed into the understanding of the 
B-cell regulatory pathways that determine their activation, differentiation and 
establishment of long-lived plasma cells as well as memory B-cells. 
The continued monitoring of individuals enrolled in the CAPRISA study will allow us to 
the study the specificities of antibodies conferring cross-reactivity as well as provide useful 
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samples from which new nMAbs could be obtained. Further studies will address the 
question of what constitutes neutralization breadth. While some studies suggest that 
neutralization breadth in HIV-1 infected patients is due to the presence of very few 
antibody specificities targeting vulnerable areas (Dhillon et al., 2007, Li et al., 2007) 
another possibility is that the accumulation of multiple “type-specific” antibodies confers 
breadth. This is an important question to address as if the latter is found to be the case, then 
the induction of a broad neutralizing antibody response will constitute even more of a 
challenge that is currently appreciated. Furthermore, such data may inform additional 
strategies to be followed in the design of an HIV vaccine. 
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APPENDIX A  Review table of subtype C viruses neutralization by nMAb  
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